{"messages":[{"status":"ok","cursor":"180","count":30,"total":8966}], "collection":[{"rel_doi":"10.1101\/2020.09.18.303420","rel_title":"The COVID-19 immune landscape is dynamically and reversibly correlated with disease severity","rel_date":"2020-09-18","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.18.303420","rel_abs":"Despite a rapidly growing body of literature on COVID-19, our understanding of the immune correlates of disease severity, course and outcome remains poor. Using mass cytometry, we assessed the immune landscape in longitudinal whole blood specimens from 59 patients presenting with acute COVID-19, and classified based on maximal disease severity. Hospitalized patients negative for SARS-CoV-2 were used as controls. We found that the immune landscape in COVID-19 forms three dominant clusters, which correlate with disease severity. Longitudinal analysis identified a pattern of productive innate and adaptive immune responses in individuals who have a moderate disease course, whereas those with severe disease have features suggestive of a protracted and dysregulated immune response. Further, we identified coordinate immune alterations accompanying clinical improvement and decline that were also seen in patients who received IL-6 pathway blockade. The hospitalized COVID-19 negative cohort allowed us to identify immune alterations that were shared between severe COVID-19 and other critically ill patients. Collectively, our findings indicate that selection of immune interventions should be based in part on disease presentation and early disease trajectory due to the profound differences in the immune response in those with mild to moderate disease and those with the most severe disease.","rel_num_authors":10,"rel_authors":[{"author_name":"Hamid Bolouri","author_inst":"Benaroya Research Institute at Virginia Mason"},{"author_name":"Cate Speake","author_inst":"Benaroya Research Institute at Virginia Mason"},{"author_name":"David Skibinski","author_inst":"Benaroya Research Institute at Virginia Mason"},{"author_name":"S Alice Long","author_inst":"Benaroya Research Institute at Virginia Mason"},{"author_name":"Anne M Hocking","author_inst":"Benaroya Research Institute at Virginia Mason"},{"author_name":"Daniel J Campbell","author_inst":"Benaroya Research Institute at Virginia Mason"},{"author_name":"Jessica A Hamerman","author_inst":"Benaroya Research Institute at Virginia Mason"},{"author_name":"Uma Malhotra","author_inst":"Virginia Mason Medical Center"},{"author_name":"Jane H Buckner","author_inst":"Benaroya Research Institute at Virginia Mason"},{"author_name":"- BRI COVID-19 Research Team","author_inst":"-"}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"immunology"},{"rel_doi":"10.1101\/2020.09.18.302398","rel_title":"Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells","rel_date":"2020-09-18","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.18.302398","rel_abs":"The SARS coronavirus 2 (SARS-CoV-2) has caused an ongoing global pandemic with currently 29 million confirmed cases and close to a million deaths. At this time, there are no FDA-approved vaccines or therapeutics for COVID-19, but Emergency Use Authorization has been granted for remdesivir, a broad-spectrum antiviral nucleoside analog. However, remdesivir is only moderately efficacious against SARS-CoV-2 in the clinic, and improved treatment strategies are urgently needed. To accomplish this goal, we devised a strategy to identify compounds that act synergistically with remdesivir in preventing SARS-CoV-2 replication. We conducted combinatorial high-throughput screening in the presence of submaximal remdesivir concentrations, using a human lung epithelial cell line infected with a clinical isolate of SARS-CoV-2. We identified 20 approved drugs that act synergistically with remdesivir, many with favorable pharmacokinetic and safety profiles. Strongest effects were observed with established antivirals, Hepatitis C virus nonstructural protein 5 A (HCV NS5A) inhibitors velpatasvir and elbasvir. Combination with their partner drugs sofosbuvir and grazoprevir further increased efficacy, increasing remdesivirs apparent potency 25-fold. We therefore suggest that the FDA-approved Hepatitis C therapeutics Epclusa (velpatasvir\/sofosbuvir) and Zepatier (elbasvir\/grazoprevir) should be fast-tracked for clinical evaluation in combination with remdesivir to improve treatment of acute SARS-CoV-2 infections.","rel_num_authors":10,"rel_authors":[{"author_name":"Xammy Nguyenla","author_inst":"University of California, Berkeley"},{"author_name":"Eddie Wehri","author_inst":"University of California, Berkeley"},{"author_name":"Erik Van Dis","author_inst":"University of California, Berkeley"},{"author_name":"Scott Biering","author_inst":"University of California, Berkeley"},{"author_name":"Livia H Yamashiro","author_inst":"UC Berkeley"},{"author_name":"Julien Stroumza","author_inst":"University of California, Berkeley"},{"author_name":"Claire Dugast-Darzacq","author_inst":"University of California, Berkeley"},{"author_name":"Thomas Graham","author_inst":"University of California, Berkeley"},{"author_name":"Sarah Stanley","author_inst":"University of California, Berkeley"},{"author_name":"Julia Schaletzky","author_inst":"University of California, Berkeley"}],"version":"1","license":"cc_by_nd","type":"new results","category":"microbiology"},{"rel_doi":"10.1101\/2020.09.18.301952","rel_title":"A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro","rel_date":"2020-09-18","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.18.301952","rel_abs":"Effective intervention strategies are urgently needed to control the COVID-19 pandemic. Human angiotensin-converting enzyme 2 (ACE2) is a carboxypeptidase that forms a dimer and serves as the cellular receptor for SARS-CoV-2. It is also a key negative regulator of the renin-angiotensin system (RAS), conserved in mammals, which modulates vascular functions. We report here the properties of a trimeric ACE2 variant, created by a structure-based approach, with binding affinity of ~60 pM for the spike (S) protein of SARS-CoV-2, while preserving the wildtype peptidase activity as well as the ability to block activation of angiotensin II receptor type 1 in the RAS. Moreover, the engineered ACE2 potently inhibits infection of SARS-CoV-2 in cell culture. These results suggest that engineered, trimeric ACE2 may be a promising anti-SARS-CoV-2 agent for treating COVID-19.","rel_num_authors":10,"rel_authors":[{"author_name":"Jianming Lu","author_inst":"Codex BioSolutions, Inc., 401 Professional Drive, Gaithersburg, MD 20879"},{"author_name":"Rebecca I. Johnson","author_inst":"Boston University School of Medicine, 620 Albany Street, Boston, MA 02118"},{"author_name":"Lindsay G.A. McKay","author_inst":"Boston University School of Medicine, 620 Albany Street, Boston, MA 02118"},{"author_name":"Nadia Storm","author_inst":"Boston University School of Medicine, 620 Albany Street, Boston, MA 02118"},{"author_name":"Christy L. Lavine","author_inst":"Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02115"},{"author_name":"Shen Lu","author_inst":"Codex BioSolutions, Inc., 401 Professional Drive, Gaithersburg, MD 20879"},{"author_name":"Brian D. Quinlan","author_inst":"Scripps Research Institute, 130 Scripps Way, Jupiter, FL 33458"},{"author_name":"Michael Farzan","author_inst":"Scripps Research Institute, 130 Scripps Way, Jupiter, FL 33458"},{"author_name":"Michael S. Seaman","author_inst":"Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02115"},{"author_name":"Anthony Griffiths","author_inst":"Boston University School of Medicine, 620 Albany Street, Boston, MA 02118"}],"version":"1","license":"cc_no","type":"new results","category":"microbiology"},{"rel_doi":"10.1101\/2020.09.15.20195511","rel_title":"Inflammatory leptomeningeal cytokines mediate delayed COVID-19 encephalopathy","rel_date":"2020-09-18","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.15.20195511","rel_abs":"SARS-CoV-2 infection induces a wide spectrum of neurologic dysfunction. Here we show that a particularly vulnerable population with neurologic manifestations of COVID-19 harbor an influx of inflammatory cytokines within the cerebrospinal fluid in the absence of viral neuro-invasion. The majority of these inflammatory mediators are driven by type 2 interferon and are known to induce neuronal injury in other disease models. Levels of matrix metalloproteinase-10 within the spinal fluid correlate with the degree of neurologic dysfunction. Furthermore, this neuroinflammatory process persists weeks following convalescence from the acute respiratory infection. These prolonged neurologic sequelae following a systemic cytokine release syndrome lead to long-term neurocognitive dysfunction with a wide range of phenotypes.","rel_num_authors":12,"rel_authors":[{"author_name":"Jan Remsik","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Jessica A Wilcox","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"N. Esther Babady","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Tracy McMillen","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Behroze A Vachha","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Neil A Halpern","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Vikram Dhawan","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Marc Rosenblum","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Christine A. Iacobuzio-Donahue","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Edward K Avila","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Bianca Santomasso","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Adrienne Boire","author_inst":"Memorial Sloan Kettering Cancer Center"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"neurology"},{"rel_doi":"10.1101\/2020.09.16.20195552","rel_title":"How the clinical research community responded to the COVID-19 pandemic: An analysis of the COVID-19 clinical studies in ClinicalTrials.gov","rel_date":"2020-09-18","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.16.20195552","rel_abs":"Objective: The novel coronavirus disease (COVID-19), broke out in December 2019, is a global pandemic. Rapidly in the past few months, a large number of clinical studies have been initiated worldwide to find effective therapeutics, vaccines, and preventive strategies. In this study, we aim to understand the landscape of COVID-19 clinical research and identify the gaps and issues that may cause difficulty in recruitment and the lack of population representativeness. Materials and Methods: We analyzed 2,034 COVID-19 studies registered in the largest public registry - ClinicalTrials.gov. Leveraging natural language processing, descriptive analysis, association analysis, and clustering analysis, we characterized COVID-19 clinical studies by phase and design features. Particularly, we analyzed their eligibility criteria to understand: (1) whether they considered the reported underlying health conditions that may lead to severe illnesses, and (2) if these studies excluded older adults, either explicitly or implicitly, which may reduce the generalizability of these studies in older adults. Results: The 5 most frequently tested drugs are Hydroxychloroquine (N=148), Azithromycin (N=46), Tocilizumab (N=29), Lopinavir (N=20), and Ritonavir (N=20). Most trials did not have an upper age limit and did not exclude patients with common chronic conditions such as hypertension and diabetes that are prevalent in older adults. However, known risk factors that may lead to severe illnesses have not been adequately considered by existing studies. Conclusions: A careful examination of the registered COVID-19 clinical studies can identify the research gaps and inform future COVID-19 trial design towards balanced internal validity and generalizability.","rel_num_authors":6,"rel_authors":[{"author_name":"Zhe He","author_inst":"Florida State University"},{"author_name":"Fnu Erdengasileng","author_inst":"Florida State University"},{"author_name":"Xiao Luo","author_inst":"Indiana University Purdue University Indianapolis"},{"author_name":"Aiwen Xing","author_inst":"Florida State University"},{"author_name":"Neil Charness","author_inst":"Florida State University"},{"author_name":"Jiang Bian","author_inst":"University of Florida"},{"author_name":"Vikram Dhawan","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Marc Rosenblum","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Christine A. Iacobuzio-Donahue","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Edward K Avila","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Bianca Santomasso","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Adrienne Boire","author_inst":"Memorial Sloan Kettering Cancer Center"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"health informatics"},{"rel_doi":"10.1101\/2020.09.16.20115972","rel_title":"CLINICALLY DISTINCT COVID-19 CASES SHARE STRIKINGLY SIMILAR IMMUNE RESPONSE PROGRESSION: A FOLLOW-UP ANALYSIS","rel_date":"2020-09-18","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.16.20115972","rel_abs":"Inflammatory responses to the novel coronavirus SARS-CoV-2, which causes COVID-19, range from asymptomatic to severe. Here we present a follow-up analysis of a longitudinal study characterizing COVID-19 immune responses from a father and son with distinctly different clinical courses. The father required a lengthy hospital stay for severe symptoms, whereas his son had mild symptoms and no fever yet tested positive for SARS-CoV-2 for 29 days. Father and son, as well as another unrelated COVID-19 patient, displayed a robust increase of SERPING1, the transcript encoding C1 esterase inhibitor (C1-INH). We further bolstered this finding by incorporating a serum proteomics dataset and found that serum C1-INH was consistently increased in COVID-19 patients. C1-INH is a central regulator of the contact and complement systems, potentially linking COVID-19 to complement hyperactivation, fibrin clot formation, and immune depression. Furthermore, despite distinct clinical cases, significant parallels were observed in transcripts involved interferon and B cell signaling. As symptoms were resolving, widespread decreases were seen in immune-related transcripts to levels below those of healthy controls. Our study provides insight into the immune responses of likely millions of people with extremely mild symptoms who may not be aware of their infection with SARS-CoV-2 and implies a potential for long-lasting consequences that could contribute to reinfection risk.","rel_num_authors":4,"rel_authors":[{"author_name":"Melissa Hausburg","author_inst":"Swedish Medical Center"},{"author_name":"Kaysie L. Banton","author_inst":"Swedish Medical Center"},{"author_name":"Michael Roshon","author_inst":"Penrose Hospital"},{"author_name":"David Bar-Or","author_inst":"Swedish Medical Center"},{"author_name":"Neil Charness","author_inst":"Florida State University"},{"author_name":"Jiang Bian","author_inst":"University of Florida"},{"author_name":"Vikram Dhawan","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Marc Rosenblum","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Christine A. Iacobuzio-Donahue","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Edward K Avila","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Bianca Santomasso","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Adrienne Boire","author_inst":"Memorial Sloan Kettering Cancer Center"}],"version":"1","license":"cc_by_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.09.17.20196352","rel_title":"The epidemiological characteristics of COVID-19 in Libya during the ongoing-armed conflict.","rel_date":"2020-09-18","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.17.20196352","rel_abs":"Abstract Introduction: COVID-19 can have even more dire consequences in countries with ongoing armed conflict. Libya, the second largest African country, has been involved in a major conflict since 2011. This study analyzed the epidemiological situation of the COVID-19 pandemic in Libya, examined the impact of the armed conflict in Libya on the spread of the pandemic, and proposes strategies for dealing with the pandemic during this conflict. Methods: We collected the available information on all COVID-19 cases in the different regions of Libya, covering the period from March 25 to May 25, 2020. The cumulative number of cases and the daily new cases are presented in a way to illustrate the patterns and trends of COVID-19 and the effect of the ongoing armed conflict was assessed regionally. Results: A total of 698 cases of COVID-19 were reported in Libya during a period of three months. The number of cases varied from one region to another and was affected by the fighting. The largest number of cases was reported in the southern part of the country, which has been severely affected by the conflict in comparison to the eastern and western parts of the country. Conclusion: This study describes the epidemiological pattern of COVID-19 in Libya and how it has been affected by the ongoing armed conflict. This conflict seems to have hindered access to populations and thereby masked the true dimensions of the pandemic. Hence, efforts should be combined to combat these consequences.","rel_num_authors":4,"rel_authors":[{"author_name":"Mohamed A Daw Sr.","author_inst":"University of Tripoli, Faculty of Medicine"},{"author_name":"Abdallah Hussean El-Bouzedi","author_inst":"University of Tripoli, Department of Laboratory Medicine, Faculty of Biotechnology, Tripoli University, CC 82668, Tripoli, Libya"},{"author_name":"Mohamed Omar Ahmed","author_inst":"Department of Microbiology & Parasitology, Faculty of Veterinary Medicine, University of Tripoli, CC 82668 Libya."},{"author_name":"Ali Ali Alejenef","author_inst":"Department of Medicine Faculty of Medicine, Zentan , University of Aljabel Alkarbi, Libya"},{"author_name":"Neil Charness","author_inst":"Florida State University"},{"author_name":"Jiang Bian","author_inst":"University of Florida"},{"author_name":"Vikram Dhawan","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Marc Rosenblum","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Christine A. Iacobuzio-Donahue","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Edward K Avila","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Bianca Santomasso","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Adrienne Boire","author_inst":"Memorial Sloan Kettering Cancer Center"}],"version":"1","license":"cc0_ng","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.09.18.20194175","rel_title":"Metabolic stress and disease-stage specific basigin expression of peripheral blood immune cell subsets in COVID-19 patients","rel_date":"2020-09-18","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.18.20194175","rel_abs":"Coronavirus disease 2019 (COVID-19) is driven by dysregulated immune responses yet the role of immunometabolism in COVID-19 pathogenesis remains unclear. By investigating 47 patients with confirmed SARS-CoV-2 infection and 16 uninfected controls, we found an immunometabolic dysregulation specific for patients with progressed disease that was reversible in the recovery phase. Specifically, T cells and monocytes exhibited increased mitochondrial mass, accumulated intracellular ROS and these changes were accompanied by disrupted mitochondrial architecture. Basigin (CD147), but not established markers of T cell activation, was up-regulated on T cells from progressed COVID-19 patients and correlated with ROS accumulation, reflected in the transcriptome. During recovery, basigin and ROS decreased to match the uninfected controls. In vitro analyses confirmed the correlation and showed a down-regulation of ROS by dexamethasone treatment. Our findings provide evidence of a basigin-related and reversible immunometabolic dysregulation in COVID-19.","rel_num_authors":34,"rel_authors":[{"author_name":"Peter J. Siska","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Katrin Singer","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Jana Klitzke","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Nathalie Kauer","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Sonja-Maria Decking","author_inst":"Regensburg Center for Interventional Immunology, University of Regensburg, 93053 Regensburg, Germany"},{"author_name":"Christina Bruss","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Carina Matos","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Kristina Kolodova","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Alic Peuker","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Gabriele Schoenhammer","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Johanna Raithel","author_inst":"Regensburg Center for Interventional Immunology, University of Regensburg, 93053 Regensburg, Germany"},{"author_name":"Dirk Lunz","author_inst":"Department of Anesthesiology, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Bernhard Graf","author_inst":"Department of Anesthesiology, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Florian Geismann","author_inst":"Department of Internal Medicine II University Hospital Regensburg, 93053 Regensburg Germany"},{"author_name":"Matthias Lubnow","author_inst":"Department of Internal Medicine II University Hospital Regensburg, 93053 Regensburg Germany"},{"author_name":"Matthias Mack","author_inst":"Department of Nephrology, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Peter Hau","author_inst":"Wilhelm Sander-NeuroOncology Unit and Department of Neurology, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Christopher Bohr","author_inst":"Department of Otorhinolaryngology, University Hospital Regensburg, 93053 Regensburg"},{"author_name":"Ralph Burkhardt","author_inst":"Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, 93053"},{"author_name":"Andre Gessner","author_inst":"Institute for Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany"},{"author_name":"Bernd Salzberger","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Frank Hanses","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Florian Hitzenbichler","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Daniel Heudobler","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Florian Lueke","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Tobias Pukrop","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Wolfgang Herr","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Daniel Wolff","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Hendrik Poeck","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Christoph Brochhausen","author_inst":"Institute of Pathology, Electron Microscopy Unit, University of Regensburg, Germany"},{"author_name":"Petra Hoffmann","author_inst":"Regensburg Center for Interventional Immunology, University of Regensburg, 93053 Regensburg, Germany"},{"author_name":"Michael Rehli","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Marina Kreutz","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Kathrin Renner","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.09.18.20197467","rel_title":"IMPACT OF UNIVERSITY RE-OPENING ON TOTAL COMMUNITY COVID-19 BURDEN","rel_date":"2020-09-18","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.18.20197467","rel_abs":"Purpose: Post-secondary students have higher than average contacts than the general population due to congregate living, use of public transit, high-density academic and social activities, and employment in the services sector. We evaluated the impact of a large student population returning to a mid-sized city currently experiencing a low rate of COVID-19 on community health outcomes. We consider whether targeted routine or one-time screening in this population can mitigate community COVID-19 impacts. Methods: We developed a dynamic transmission model of COVID-19 subdivided into three interacting populations: general population, university students, and long-term care residents. We parameterized the model using the medical literature and expert opinion. We calibrated the model to the observed outcomes in a mid-sized Canadian city between March 1 and August 15, 2020 prior to the arrival of a relatively large post-secondary student population. We evaluated the impact of the student population (20,000 people arriving on September 1) on cumulative COVID-19 infections over the fall semester, the timing of peak infections, the timing and peak level of critical care occupancy, and the timing of re-engaged social and economic restrictions. We consider multiple scenarios with different student and general population COVID-19 prevention behaviours as well as different COVID-19 screening strategies in students. Results: In a city with low levels of COVID-19 activity, the return of a relatively large student population substantially increases the total number of COVID-19 infections in the community. In a scenario in which students immediately engage in a 24% contact reduction compared to pre-COVID levels, the total number of infections in the community increases by 87% (from 3,900 without the students to 7,299 infections with the students), with 71% of the incremental infections occurring in the general population, causing social and economic restrictions to be re-engaged 3 weeks earlier and an incremental 17 COVID-19 deaths. Scenarios in which students have an initial, short-term increase in contacts with other students before engaging in contact reduction behaviours can increase infections in the community by 150% or more. In such scenarios, screening asymptomatic students every 5 days reduces the number of infections attributable to the introduction of the university student population by 42% and delays the re-engagement of social and economic restrictions by 1 week. Compared to screening every 5 days, one-time mass screening of students prevents fewer infections, but is highly efficient in terms of infections prevented per screening test performed. Discussion: University students are highly inter-connected with the city communities in which they live and go to school, and they have a higher number of contacts than the general population. High density living environments, enthusiasm for the new school year, and relatively high rates of asymptomatic presentation may decrease their self-protective behaviours and contribute to increased community transmission of COVID-19 affecting at-risk members of the city community. Screening targeted at this population provides significant public health benefits to the community through averted infections, critical care admissions, and COVID-19 deaths.","rel_num_authors":4,"rel_authors":[{"author_name":"Lauren E Cipriano","author_inst":"University of Western Ontario"},{"author_name":"Wael M R Haddara","author_inst":"Division of Critical Care, London Health Sciences Centre"},{"author_name":"Gregory S Zaric","author_inst":"Ivey Business School, University of Western Ontario"},{"author_name":"Eva A Enns","author_inst":"Division of Health Policy and Management, University of Minnesota"},{"author_name":"Sonja-Maria Decking","author_inst":"Regensburg Center for Interventional Immunology, University of Regensburg, 93053 Regensburg, Germany"},{"author_name":"Christina Bruss","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Carina Matos","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Kristina Kolodova","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Alic Peuker","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Gabriele Schoenhammer","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Johanna Raithel","author_inst":"Regensburg Center for Interventional Immunology, University of Regensburg, 93053 Regensburg, Germany"},{"author_name":"Dirk Lunz","author_inst":"Department of Anesthesiology, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Bernhard Graf","author_inst":"Department of Anesthesiology, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Florian Geismann","author_inst":"Department of Internal Medicine II University Hospital Regensburg, 93053 Regensburg Germany"},{"author_name":"Matthias Lubnow","author_inst":"Department of Internal Medicine II University Hospital Regensburg, 93053 Regensburg Germany"},{"author_name":"Matthias Mack","author_inst":"Department of Nephrology, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Peter Hau","author_inst":"Wilhelm Sander-NeuroOncology Unit and Department of Neurology, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Christopher Bohr","author_inst":"Department of Otorhinolaryngology, University Hospital Regensburg, 93053 Regensburg"},{"author_name":"Ralph Burkhardt","author_inst":"Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, 93053"},{"author_name":"Andre Gessner","author_inst":"Institute for Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany"},{"author_name":"Bernd Salzberger","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Frank Hanses","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Florian Hitzenbichler","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Daniel Heudobler","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Florian Lueke","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Tobias Pukrop","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Wolfgang Herr","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Daniel Wolff","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Hendrik Poeck","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Christoph Brochhausen","author_inst":"Institute of Pathology, Electron Microscopy Unit, University of Regensburg, Germany"},{"author_name":"Petra Hoffmann","author_inst":"Regensburg Center for Interventional Immunology, University of Regensburg, 93053 Regensburg, Germany"},{"author_name":"Michael Rehli","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Marina Kreutz","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Kathrin Renner","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.09.18.20195024","rel_title":"SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia","rel_date":"2020-09-18","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.18.20195024","rel_abs":"Background: Georgia timely implemented effective response measures, with testing, contact tracing and isolation being the main pillar of the national response, achieving the lowest cumulative incidence of SARS-CoV-2 in the European region. Methods: We conducted a survey to estimate SARS-CoV-2 IgG antibody seroprevalence among adult residents of capital city of Tbilisi (adult population: 859,328). Participants were recruited through respondent driven sampling during May 18-27, 2020. Blood specimens were tested for SARS-CoV-2 IgG antibodies using commercially available lateral flow immunoassay (COVID-19 IgG\/IgM Rapid Test Cassette, Zhejiang Orient Gene Biotech). Crude seroprevalence was weighted by population characteristics (age, sex, district of Tbilisi) and further adjusted for test accuracy. Results: Among 1,068 adults recruited 963 (90.2%) were between 18 and 64 years-old, 682 (63.9%) women. 176 (16.5%) reported symptoms indicative of SARS-CoV-2 infection occurring in previous three months. Nine persons tested positive for IgG: crude seroprevalence: 0.84%, (95% CI: 0.33%-1.59%), weighted seroprevalence: 0.94% (95% CI: 0.37%-1.95%), weighted and adjusted for test accuracy: 1.02% (95% CI: 0.38%-2.18%). The seroprevalence estimates translate into 7,200 to 8,800 infections among adult residents of Tbilisi, which is at least 20 times higher than the number of confirmed cases. Conclusions: Low seroprevalence confirms that Georgia successfully contained spread of SARS-CoV-2 during the first wave of pandemic. Findings also suggest that undocumented cases due to asymptomatic or very mild disease account for majority of infections. Given that asymptomatic persons can potentially spread the virus, test and isolate approach should be further expanded to control the epidemic.","rel_num_authors":8,"rel_authors":[{"author_name":"Tengiz Tsertsvadze","author_inst":"1) Infectious Diseases, AIDS and Clinical Immunology Research Center; 2) Ivane Javakhishvili Tbilisi State University"},{"author_name":"Lana Gatserelia","author_inst":"Infectious Diseases, AIDS and Clinical Immunology Research Center"},{"author_name":"Marine Mirziashvili","author_inst":"Infectious Diseases, AIDS and Clinical Immunology Research Center"},{"author_name":"Natia Dvali","author_inst":"1) Infectious Diseases, AIDS and Clinical Immunology Research Center; 2) Caucasus International University"},{"author_name":"Akaki Abutidze","author_inst":"1) Infectious Diseases, AIDS and Clinical Immunology Research Center; 2) Ivane Javakhishvili Tbilisi State University"},{"author_name":"Revaz Metchurtchlishvili","author_inst":"Infectious Diseases, AIDS and Clinical Immunology Research Center"},{"author_name":"Carlos del Rio","author_inst":"Emory University"},{"author_name":"Nikoloz Chkhartishvili","author_inst":"1) Infectious Diseases, AIDS and Clinical Immunology Research Center; 2) Caucasus International University"},{"author_name":"Alic Peuker","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Gabriele Schoenhammer","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Johanna Raithel","author_inst":"Regensburg Center for Interventional Immunology, University of Regensburg, 93053 Regensburg, Germany"},{"author_name":"Dirk Lunz","author_inst":"Department of Anesthesiology, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Bernhard Graf","author_inst":"Department of Anesthesiology, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Florian Geismann","author_inst":"Department of Internal Medicine II University Hospital Regensburg, 93053 Regensburg Germany"},{"author_name":"Matthias Lubnow","author_inst":"Department of Internal Medicine II University Hospital Regensburg, 93053 Regensburg Germany"},{"author_name":"Matthias Mack","author_inst":"Department of Nephrology, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Peter Hau","author_inst":"Wilhelm Sander-NeuroOncology Unit and Department of Neurology, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Christopher Bohr","author_inst":"Department of Otorhinolaryngology, University Hospital Regensburg, 93053 Regensburg"},{"author_name":"Ralph Burkhardt","author_inst":"Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, 93053"},{"author_name":"Andre Gessner","author_inst":"Institute for Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany"},{"author_name":"Bernd Salzberger","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Frank Hanses","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Florian Hitzenbichler","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Daniel Heudobler","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Florian Lueke","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Tobias Pukrop","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Wolfgang Herr","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Daniel Wolff","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Hendrik Poeck","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Christoph Brochhausen","author_inst":"Institute of Pathology, Electron Microscopy Unit, University of Regensburg, Germany"},{"author_name":"Petra Hoffmann","author_inst":"Regensburg Center for Interventional Immunology, University of Regensburg, 93053 Regensburg, Germany"},{"author_name":"Michael Rehli","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Marina Kreutz","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Kathrin Renner","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.09.18.20191254","rel_title":"Variation in SARS-CoV-2 seroprevalence in school-children across districts, schools and classes","rel_date":"2020-09-18","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.18.20191254","rel_abs":"Importance: Understanding transmission and impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in school children is critical to implement appropriate mitigation measures. Objective: To determine the variation in SARS-CoV-2 seroprevalence in school children across districts, schools, grades, and classes, and the relationship of SARS-CoV-2 seroprevalence with self-reported symptoms. Design: Cross-sectional analysis of baseline measurements of a longitudinal cohort study (Ciao Corona) from June-July 2020. Setting: 55 randomly selected schools and classes stratified by district in the canton of Zurich, Switzerland (1.5 million inhabitants). Participants: Children, aged 6-16 years old, attending grades 1-2, 4-5 and 7-8. Exposure: Exposure to circulating SARS-CoV-2 between February and June 2020 including public lock-down and school closure (March 16-May 10, 2020). Main Outcomes and Measures: Variation in seroprevalence of SARS-CoV-2 in children across 12 cantonal districts, schools, and grades using a Luminex-based antibody test with four targets for each of IgG, IgA and IgM. Clustering of cases within classes. Analysis of associations of seropositivity and symptoms. Comparison of seroprevalence with a randomly selected adult population, based on Luminex-based IgG and IgA antibody test of Corona Immunitas. Results: In total, 55 schools and 2585 children were recruited (1337 girls, median age 11, age range 6-16 years). Overall seroprevalence was 2.8 % (95% CI 1.6-4.1%), ranging from 1.0% to 4.5% across districts. Seroprevalence was 3.8% (1.9-6.1%) in grades 1-2, 2.5% (1.1-4.2%) in grades 4-5, and 1.5% (0.5-3.0%) in grades 7-8. At least one case was present in 36\/55 tested schools and in 43\/128 classes with [&ge;]50% participation rate and [&ge;]5 children tested. 73% of children reported COVID-19 compatible symptoms since January 2020, but none were reported more frequently in seropositive compared to seronegative children. Seroprevalence of children was very similar to seroprevalence of randomly selected adults in the same region in June-July 2020, measured with the same Corona Immunitas test, combining IgG and IgA (3.1%, 95% CI 1.4-5.4%, versus 3.3%, 95% CI 1.4-5.5%). Conclusions and Relevance: Seroprevalence was inversely related to age and revealed a dark figure of around 90 when compared to 0.03% confirmed PCR+ cases in children in the same area by end of June. We did not find clustering of SARS-CoV-2 seropositive cases in schools so far, but the follow-up of this school-based study will shed more light on transmission within and outside schools. Trial registration: ClinicalTrials.gov Identifier: NCT04448717, registered June 26, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04448717","rel_num_authors":16,"rel_authors":[{"author_name":"Agne Ulyte","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Thomas Radtke","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Irene A Abela","author_inst":"Institute of Medical Virology, University of Zurich"},{"author_name":"Sarah H Haile","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Jacob Blankenberger","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Ruedi Jung","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Celine Capelli","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Christoph Berger","author_inst":"University Children Hospital Zurich"},{"author_name":"Anja Frei","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Michael Huber","author_inst":"Institute of Medical Virology, University of Zurich"},{"author_name":"Merle Schanz","author_inst":"Institute of Medical Virology, University of Zurich"},{"author_name":"Magdalena Schwarzmueller","author_inst":"Institute of Medical Virology, University of Zurich"},{"author_name":"Alexandra Trkola","author_inst":"Institute of Medical Virology, University of Zurich"},{"author_name":"Jan Fehr","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Milo A Puhan","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Susi Kriemler","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Peter Hau","author_inst":"Wilhelm Sander-NeuroOncology Unit and Department of Neurology, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Christopher Bohr","author_inst":"Department of Otorhinolaryngology, University Hospital Regensburg, 93053 Regensburg"},{"author_name":"Ralph Burkhardt","author_inst":"Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, 93053"},{"author_name":"Andre Gessner","author_inst":"Institute for Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany"},{"author_name":"Bernd Salzberger","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Frank Hanses","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Florian Hitzenbichler","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Daniel Heudobler","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Florian Lueke","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Tobias Pukrop","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Wolfgang Herr","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Daniel Wolff","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Hendrik Poeck","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Christoph Brochhausen","author_inst":"Institute of Pathology, Electron Microscopy Unit, University of Regensburg, Germany"},{"author_name":"Petra Hoffmann","author_inst":"Regensburg Center for Interventional Immunology, University of Regensburg, 93053 Regensburg, Germany"},{"author_name":"Michael Rehli","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Marina Kreutz","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Kathrin Renner","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"}],"version":"1","license":"cc_by_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.09.18.20186866","rel_title":"Clinical-epidemiological and treatment characteristics of children with COVID-19 in a tertiary referral center in Peru","rel_date":"2020-09-18","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.18.20186866","rel_abs":"Introduction The COVID-19 pandemic has a great impact on children's health. This study describes the clinical, epidemiological and treatment characteristics of children presenting COVID-19 at the Instituto Nacional de Salud del Nino San Borja (INSN-SB) Methods This was a retrospective study of patients with a confirmed diagnosis of COVID-19 from March to July 2020. Demographic, clinical, laboratory, radiological, and treatment information were collected. Data analysis included descriptive statistics and bivariate analysis to determine differences between patients in general wards and the intensive care unit (ICU). Results We included 91 patients, 33 being females (36.3%). The most affected age group was children > 2 years of age (63 cases) with a median age of 6 years (IQR 3-10), and 61.5% were from Lima. The previous contact was determined in 30.8% of cases. A positive SARS CoV-2 PCR result was obtained in 50.6%. The presence of comorbidity was 53.8%. The most frequent symptoms were: fever (39.6%), general malaise (23.1%), cough (19.8%), and respiratory distress (14.3%). The presence of multisystem inflammatory syndrome in children (MIS-C) was confirmed in 6 patients. Antibiotics were administered in 76.9%. The most frequent radiological pattern was bilateral interstitial infiltrates (57.7%). Mortality was higher in patients in the ICU than in the hospitalization ward (27.3% vs. 4.3%, respectively; p = 0.02) Conclusions COVID-19 in children presents mild and moderate clinical manifestations. The presence of comorbidity is an important factor for hospitalization, and mortality is high upon admission to critical care units.","rel_num_authors":12,"rel_authors":[{"author_name":"Christian Chiara-Chilet","author_inst":"Instituto Nacional de Salud del Nino San Borja"},{"author_name":"Medalit Luna-Vilchez","author_inst":"Instituto Nacional de Salud del Ni\u00f1o San Borja"},{"author_name":"Julio Maquera-Afaray","author_inst":"Instituto Nacional de Salud del Ni\u00f1o San Borja"},{"author_name":"Blanca Salazar-Mesones","author_inst":"Instituto Nacional de Salud del Ni\u00f1o San Borja"},{"author_name":"Diana Portillo-Alvarez","author_inst":"Instituto Nacional de Salud del Ni\u00f1o San Borja"},{"author_name":"Ramiro Priale-Miranda","author_inst":"Instituto Nacional de Salud del Ni\u00f1o San Borja"},{"author_name":"Franklin Mendoza-Torres","author_inst":"Instituto Nacional de Salud del Ni\u00f1o San Borja"},{"author_name":"Aldo Munayco-Perez","author_inst":"Instituto Nacional de Salud del Ni\u00f1o San Borja"},{"author_name":"Yeny Baca-Cama","author_inst":"Instituto Nacional de Salud del Ni\u00f1o San Borja"},{"author_name":"Mitsi Santiago-Abad","author_inst":"Instituto Nacional de Salud del Ni\u00f1o San Borja"},{"author_name":"Jose W Lopez","author_inst":"Universidad Cientifica del Sur"},{"author_name":"- Pediatric COVID-19 Working Group INSN SB","author_inst":""},{"author_name":"Alexandra Trkola","author_inst":"Institute of Medical Virology, University of Zurich"},{"author_name":"Jan Fehr","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Milo A Puhan","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Susi Kriemler","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Peter Hau","author_inst":"Wilhelm Sander-NeuroOncology Unit and Department of Neurology, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Christopher Bohr","author_inst":"Department of Otorhinolaryngology, University Hospital Regensburg, 93053 Regensburg"},{"author_name":"Ralph Burkhardt","author_inst":"Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, 93053"},{"author_name":"Andre Gessner","author_inst":"Institute for Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany"},{"author_name":"Bernd Salzberger","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Frank Hanses","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Florian Hitzenbichler","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Daniel Heudobler","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Florian Lueke","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Tobias Pukrop","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Wolfgang Herr","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Daniel Wolff","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Hendrik Poeck","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Christoph Brochhausen","author_inst":"Institute of Pathology, Electron Microscopy Unit, University of Regensburg, Germany"},{"author_name":"Petra Hoffmann","author_inst":"Regensburg Center for Interventional Immunology, University of Regensburg, 93053 Regensburg, Germany"},{"author_name":"Michael Rehli","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Marina Kreutz","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Kathrin Renner","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"pediatrics"},{"rel_doi":"10.1101\/2020.09.14.20194670","rel_title":"Estimating Risk of Mechanical Ventilation and Mortality Among Adult COVID-19 patients Admitted to Mass General Brigham: The VICE and DICE Scores","rel_date":"2020-09-17","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.09.14.20194670","rel_abs":"Background: Risk stratification of COVID-19 patients upon hospital admission is key for their successful treatment and efficient utilization of hospital resources. Objective: To evaluate the risk factors associated with ventilation need and mortality. Design, setting and participants: We established a retrospective cohort of COVID-19 patients from Mass General Brigham hospitals. Demographic, clinical, and admission laboratory data were obtained from electronic medical records of patients admitted to hospital with laboratory-confirmed COVID-19 before May 19th, 2020. Using patients admitted to Massachusetts General Hospital (MGH, derivation cohort), multivariable logistic regression analyses were used to construct the Ventilation in COVID Estimator (VICE) and Death in COVID Estimator (DICE) risk scores. Measurements: The primary outcomes were ventilation status and death. Results: The entire cohort included 1042 patients (median age, 64 years; 56.8% male). The derivation and validation cohorts for the risk scores included 578 and 464 patients, respectively. We found seven factors to be independently predictive for ventilation requirement (diabetes mellitus, dyspnea, alanine aminotransferase, troponin, C-reactive protein, neutrophil-lymphocyte ratio, and lactate dehydrogenase), and 10 factors to be predictors of in-hospital mortality (age, sex, diabetes mellitus, chronic statin use, albumin, C-reactive protein, neutrophil-lymphocyte ratio, mean corpuscular volume, platelet count, and procalcitonin). Using these factors, we constructed the VICE and DICE risk scores, which performed with C-statistics of at least 0.8 in our cohorts. Importantly, the chronic use of a statin was associated with protection against death due to COVID-19. The VICE and DICE score calculators have been placed on an interactive website freely available to the public (https:\/\/covid-calculator.com\/). Limitations: One potential limitation is the modest sample sizes in both our derivation and validation cohorts. Conclusion: The risk scores developed in this study may help clinicians more appropriately determine which COVID-19 patients will need to be managed with greater intensity.","rel_num_authors":8,"rel_authors":[{"author_name":"Christopher J Nicholson","author_inst":"Massachusetts General Hospital\/Harvard Medical School"},{"author_name":"Luke Wooster","author_inst":"Case Western Reserve University School of Medicine"},{"author_name":"Haakon H Sigurslid","author_inst":"Massachusetts General Hospital"},{"author_name":"Rebecca F Li","author_inst":"Massachusetts General Hospital"},{"author_name":"Wanlin Jiang","author_inst":"Massachusetts General Hospital"},{"author_name":"Wenjie Tian","author_inst":"Massachusetts General Hospital"},{"author_name":"Christian Lino Cardenas","author_inst":"MassachusettsGeneral Hospital"},{"author_name":"Rajeev Malhotra","author_inst":"Massachusetts General Hospital\/Harvard Medical School"},{"author_name":"Yeny Baca-Cama","author_inst":"Instituto Nacional de Salud del Ni\u00f1o San Borja"},{"author_name":"Mitsi Santiago-Abad","author_inst":"Instituto Nacional de Salud del Ni\u00f1o San Borja"},{"author_name":"Jose W Lopez","author_inst":"Universidad Cientifica del Sur"},{"author_name":"- Pediatric COVID-19 Working Group INSN SB","author_inst":""},{"author_name":"Alexandra Trkola","author_inst":"Institute of Medical Virology, University of Zurich"},{"author_name":"Jan Fehr","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Milo A Puhan","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Susi Kriemler","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Peter Hau","author_inst":"Wilhelm Sander-NeuroOncology Unit and Department of Neurology, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Christopher Bohr","author_inst":"Department of Otorhinolaryngology, University Hospital Regensburg, 93053 Regensburg"},{"author_name":"Ralph Burkhardt","author_inst":"Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, 93053"},{"author_name":"Andre Gessner","author_inst":"Institute for Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany"},{"author_name":"Bernd Salzberger","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Frank Hanses","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Florian Hitzenbichler","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Daniel Heudobler","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Florian Lueke","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Tobias Pukrop","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Wolfgang Herr","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Daniel Wolff","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Hendrik Poeck","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Christoph Brochhausen","author_inst":"Institute of Pathology, Electron Microscopy Unit, University of Regensburg, Germany"},{"author_name":"Petra Hoffmann","author_inst":"Regensburg Center for Interventional Immunology, University of Regensburg, 93053 Regensburg, Germany"},{"author_name":"Michael Rehli","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Marina Kreutz","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Kathrin Renner","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"intensive care and critical care medicine"},{"rel_doi":"10.1101\/2020.09.17.300996","rel_title":"Monocytes and macrophages, targets of SARS-CoV-2: the clue for Covid-19 immunoparalysis","rel_date":"2020-09-17","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.17.300996","rel_abs":"To date, the Covid-19 pandemic affected more than 18 million individuals and caused more than 690, 000 deaths. Its clinical expression is pleiomorphic and severity is related to age and comorbidities such as diabetes and hypertension. The pathophysiology of the disease relies on aberrant activation of immune system and lymphopenia that has been recognized as a prognosis marker. We wondered if the myeloid compartment was affected in Covid-19 and if monocytes and macrophages could be infected by SARS-CoV-2. We show here that SARS-CoV-2 efficiently infects monocytes and macrophages without any cytopathic effect. Infection was associated with the secretion of immunoregulatory cytokines (IL-6, IL-10, TGF-{beta}) and the induction of a macrophagic specific transcriptional program characterized by the upregulation of M2-type molecules. In addition, we found that in vitro macrophage polarization did not account for the permissivity to SARS-CoV-2, since M1-and M2-type macrophages were similarly infected. Finally, in a cohort of 76 Covid-19 patients ranging from mild to severe clinical expression, all circulating monocyte subsets were decreased, likely related to massive emigration into tissues. Monocytes from Covid-19 patients exhibited decreased expression of HLA-DR and increased expression of CD163, irrespective of the clinical status. Hence, SARS-CoV-2 drives circulating monocytes and macrophages inducing immunoparalysis of the host for the benefit of Covid-19 disease progression.","rel_num_authors":12,"rel_authors":[{"author_name":"Asma Boumaza","author_inst":"Aix-Marseille Univ, IRD, APHM, MEPHI, IHU-Mediterranee Infection"},{"author_name":"Laetitia Gay","author_inst":"Aix-Marseille Univ, IRD, APHM, MEPHI, IHU-Mediterranee Infection"},{"author_name":"Soraya Mezouar","author_inst":"Aix-Marseille Univ, IRD, APHM, MEPHI, IHU-Mediterranee Infection"},{"author_name":"Aissatou Bailo Diallo","author_inst":"Aix-Marseille Univ, IRD, APHM, MEPHI, IHU-Mediterranee Infection"},{"author_name":"Moise Michel","author_inst":"Aix-Marseille Univ, IRD, APHM, MEPHI, IHU-Mediterranee Infection"},{"author_name":"Benoit Desnues","author_inst":"Aix-Marseille Univ, IRD, APHM, MEPHI, IHU-Mediterranee Infection"},{"author_name":"Didier Raoult","author_inst":"Aix-Marseille Univ, IRD, APHM, MEPHI, IHU-Mediterranee Infection"},{"author_name":"Bernard LA SCOLA","author_inst":"Aix-Marseille Univ, IRD, APHM, MEPHI, IHU-Mediterranee Infection"},{"author_name":"Philippe Halfon","author_inst":"Aix-Marseille Univ, IRD, APHM, MEPHI, IHU-Mediterranee Infection"},{"author_name":"Joana Vitte","author_inst":"Aix-Marseille Univ, IRD, APHM, MEPHI, IHU-Mediterranee Infection"},{"author_name":"Daniel Olive","author_inst":"Centre de Recherche en Cancerologie de Marseille, CRCM"},{"author_name":"Jean-Louis Mege","author_inst":"Aix-Marseille Univ, IRD, APHM, MEPHI, IHU-Mediterranee Infection"},{"author_name":"Alexandra Trkola","author_inst":"Institute of Medical Virology, University of Zurich"},{"author_name":"Jan Fehr","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Milo A Puhan","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Susi Kriemler","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Peter Hau","author_inst":"Wilhelm Sander-NeuroOncology Unit and Department of Neurology, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Christopher Bohr","author_inst":"Department of Otorhinolaryngology, University Hospital Regensburg, 93053 Regensburg"},{"author_name":"Ralph Burkhardt","author_inst":"Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, 93053"},{"author_name":"Andre Gessner","author_inst":"Institute for Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany"},{"author_name":"Bernd Salzberger","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Frank Hanses","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Florian Hitzenbichler","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Daniel Heudobler","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Florian Lueke","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Tobias Pukrop","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Wolfgang Herr","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Daniel Wolff","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Hendrik Poeck","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Christoph Brochhausen","author_inst":"Institute of Pathology, Electron Microscopy Unit, University of Regensburg, Germany"},{"author_name":"Petra Hoffmann","author_inst":"Regensburg Center for Interventional Immunology, University of Regensburg, 93053 Regensburg, Germany"},{"author_name":"Michael Rehli","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Marina Kreutz","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Kathrin Renner","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"immunology"},{"rel_doi":"10.1101\/2020.09.16.300871","rel_title":"Distinct SARS-CoV-2 Antibody Reactivity Patterns in Coronavirus Convalescent Plasma Revealed by a Coronavirus Antigen Microarray","rel_date":"2020-09-17","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.16.300871","rel_abs":"A coronavirus antigen microarray (COVAM) was constructed containing 11 SARS-CoV-2, 5 SARS-1, 5 MERS, and 12 seasonal coronavirus recombinant proteins. The array is designed to measure immunoglobulin isotype and subtype levels in serum or plasma samples against each of the individual antigens printed on the array. We probed the COVAM with COVID-19 convalescent plasma (CCP) collected from 99 donors who recovered from a PCR+ confirmed SARS-CoV-2 infection. The results were analyzed using two computational approaches, a generalized linear model (glm) and Random Forest (RF) prediction model, to classify individual specimens as either Reactive or Non-Reactive against the SARS-CoV-2 antigens. A training set of 88 pre-COVID-19 specimens (PreCoV) collected in August 2019 and102 positive specimens from SARS-CoV-2 PCR+ confirmed COVID-19 cases was used for these analyses. Results compared with an FDA emergency use authorized (EUA) SARS-CoV2 S1-based total Ig chemiluminescence immunoassay (Ortho Clinical Diagnostics VITROS(R) Anti-SARS-CoV-2 Total, CoV2T) and with a SARS-CoV-2 S1-S2 spike-based pseudovirus micro neutralization assay (SARS-CoV-2 reporter viral particle neutralization titration (RVPNT) showed high concordance between the 3 assays. Three CCP specimens that were negative by the VITROS CoV2T immunoassay were also negative by both COVAM and the RVPNT assay. Concordance between VITROS CoV2T and COVAM was 96%, VITROS CoV2T and RVPNT 93%, and RVPNT and COVAM 95%. The discordances were all weakly reactive samples near the cutoff threshold of the VITROS CoV2T immunoassay. The multiplex COVAM allows CCP to be grouped according to antibody reactivity patterns against 11 SARS-CoV-2 antigens. Unsupervised K-means analysis, via the gap statistics, as well as hierarchical clustering analysis revealed 3 main clusters with distinct reactivity intensities and patterns. These patterns were not recapitulated by adjusting the VITROS CoV2T or RVPNT assay thresholds. Plasma classified according to these reactivity patterns may be better associated with CCP treatment efficacy than antibody levels alone. The use of a SARS-CoV-2 antigen array may be useful to qualify CCP for administration as a treatment for acute COVID-19 and to interrogate vaccine immunogenicity and performance in preclinical and clinical studies to understand and recapitulate antibody responses associated with protection from infection and disease.","rel_num_authors":12,"rel_authors":[{"author_name":"Rafael Ramiro de Assis","author_inst":"University of California, Irvine"},{"author_name":"Aarti Jain","author_inst":"University of California, Irvine"},{"author_name":"Rie Nakajima","author_inst":"University of California, Irvine"},{"author_name":"Algis Jasinskas","author_inst":"University of California, Irvine"},{"author_name":"Saahir Khan","author_inst":"University of Southern California"},{"author_name":"Larry J Dumont","author_inst":"Vitalant Research Institute"},{"author_name":"Kathleen Kelly","author_inst":"Vitalant Research Institute"},{"author_name":"Graham Simmons","author_inst":"Vitalant Research Institute"},{"author_name":"Mars Stone","author_inst":"Vitalant Research Institute"},{"author_name":"Clara Di Germanio","author_inst":"Vitalant Research Institute"},{"author_name":"Michael P Busch","author_inst":"Vitalant Research Institute"},{"author_name":"Philip L Felgner","author_inst":"University of California, Irvine"},{"author_name":"Alexandra Trkola","author_inst":"Institute of Medical Virology, University of Zurich"},{"author_name":"Jan Fehr","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Milo A Puhan","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Susi Kriemler","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Peter Hau","author_inst":"Wilhelm Sander-NeuroOncology Unit and Department of Neurology, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Christopher Bohr","author_inst":"Department of Otorhinolaryngology, University Hospital Regensburg, 93053 Regensburg"},{"author_name":"Ralph Burkhardt","author_inst":"Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, 93053"},{"author_name":"Andre Gessner","author_inst":"Institute for Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany"},{"author_name":"Bernd Salzberger","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Frank Hanses","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Florian Hitzenbichler","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Daniel Heudobler","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Florian Lueke","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Tobias Pukrop","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Wolfgang Herr","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Daniel Wolff","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Hendrik Poeck","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Christoph Brochhausen","author_inst":"Institute of Pathology, Electron Microscopy Unit, University of Regensburg, Germany"},{"author_name":"Petra Hoffmann","author_inst":"Regensburg Center for Interventional Immunology, University of Regensburg, 93053 Regensburg, Germany"},{"author_name":"Michael Rehli","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Marina Kreutz","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Kathrin Renner","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"}],"version":"1","license":"cc_by_nd","type":"new results","category":"immunology"},{"rel_doi":"10.1101\/2020.09.16.300319","rel_title":"A soluble ACE2 microbody protein fused to a single immunoglobulin Fc domain is a potent inhibitor of SARS-CoV-2 infection in cell culture","rel_date":"2020-09-17","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.16.300319","rel_abs":"Soluble forms of ACE2 have recently been shown to inhibit SARS-CoV-2 infection. We report on an improved soluble ACE2, termed a \"microbody\" in which the ACE2 ectodomain is fused to Fc domain 3 of the immunoglobulin heavy chain. The protein is smaller than previously described ACE2-Ig Fc fusion proteins and contains an H345A mutation in the ACE2 catalytic active site that inactivates the enzyme without reducing its affinity for the SARS-CoV-2 spike. The disulfide-bonded ACE2 microbody protein inhibited entry of lentiviral SARS-CoV-2 spike protein pseudotyped virus and live SARS-CoV-2 with a potency 10-fold higher than unmodified soluble ACE2 and was active after initial virus binding to the cell. The ACE2 microbody inhibited the entry of ACE2-specific {beta} coronaviruses and viruses with the high infectivity variant D614G spike. The ACE2 microbody may be a valuable therapeutic for COVID-19 that is active against SARS-CoV-2 variants and future coronaviruses that may arise.","rel_num_authors":7,"rel_authors":[{"author_name":"Takuya Tada","author_inst":"NYU Langone Medical Center"},{"author_name":"Chen Fan","author_inst":"Weill Cornell Medical College"},{"author_name":"Ramanjit Kaur","author_inst":"NYU Langone Medical Center"},{"author_name":"Kenneth A Stapleford","author_inst":"NYU Langone Medical Center"},{"author_name":"Harry Gristick","author_inst":"California Institute of Technology"},{"author_name":"Crina Nimigean","author_inst":"Weill Cornell Medical College"},{"author_name":"Nathaniel R Landau","author_inst":"NYU Langone Medical Center"},{"author_name":"Graham Simmons","author_inst":"Vitalant Research Institute"},{"author_name":"Mars Stone","author_inst":"Vitalant Research Institute"},{"author_name":"Clara Di Germanio","author_inst":"Vitalant Research Institute"},{"author_name":"Michael P Busch","author_inst":"Vitalant Research Institute"},{"author_name":"Philip L Felgner","author_inst":"University of California, Irvine"},{"author_name":"Alexandra Trkola","author_inst":"Institute of Medical Virology, University of Zurich"},{"author_name":"Jan Fehr","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Milo A Puhan","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Susi Kriemler","author_inst":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich"},{"author_name":"Peter Hau","author_inst":"Wilhelm Sander-NeuroOncology Unit and Department of Neurology, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Christopher Bohr","author_inst":"Department of Otorhinolaryngology, University Hospital Regensburg, 93053 Regensburg"},{"author_name":"Ralph Burkhardt","author_inst":"Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, 93053"},{"author_name":"Andre Gessner","author_inst":"Institute for Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany"},{"author_name":"Bernd Salzberger","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Frank Hanses","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Florian Hitzenbichler","author_inst":"Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Daniel Heudobler","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Florian Lueke","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Tobias Pukrop","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Wolfgang Herr","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Daniel Wolff","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Hendrik Poeck","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Christoph Brochhausen","author_inst":"Institute of Pathology, Electron Microscopy Unit, University of Regensburg, Germany"},{"author_name":"Petra Hoffmann","author_inst":"Regensburg Center for Interventional Immunology, University of Regensburg, 93053 Regensburg, Germany"},{"author_name":"Michael Rehli","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Marina Kreutz","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Kathrin Renner","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"}],"version":"1","license":"cc_no","type":"new results","category":"microbiology"},{"rel_doi":"10.1101\/2020.09.17.299933","rel_title":"Identification of novel antiviral drug combinations in vitro and tracking their development","rel_date":"2020-09-17","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.17.299933","rel_abs":"Combination therapies have become a standard for the treatment for HIV and HCV infections. They are advantageous over monotherapies due to better efficacy and reduced toxicity, as well as the ability to prevent the development of resistant viral strains and to treat viral co-infections. Here, we identify several new synergistic combinations against emerging and re-emerging viral infections in vitro. We observed synergistic activity of nelfinavir with investigational drug EIDD-2801 and convalescent serum against SARS-CoV-2 infection in human lung epithelial Calu-3 cells. We also demonstrated synergistic activity of vemurafenib combination with emetine, homoharringtonine, gemcitabine, or obatoclax against echovirus 1 infection in human lung epithelial A549 cells. We also found that combinations of sofosbuvir with brequinar and niclosamide were synergistic against HCV infection in hepatocyte derived Huh-7.5 cells, whereas combinations of monensin with lamivudine and tenofovir were synergistic against HIV-1 infection in human cervical TZM-bl cells. Finally, we present an online resource that summarizes novel and known antiviral drug combinations and their developmental status. Overall, the development of combinational therapies could have a global impact improving the preparedness and protection of the general population from emerging and re-emerging viral threats.","rel_num_authors":26,"rel_authors":[{"author_name":"Aleksandr Ianevski","author_inst":"NTNU"},{"author_name":"Rouan Yao","author_inst":"NTNU"},{"author_name":"Svetlana Biza","author_inst":"NTNU"},{"author_name":"Eva Zusinaite","author_inst":"TUIT"},{"author_name":"Andres Mannik","author_inst":"Icosagen"},{"author_name":"Gaily Kivi","author_inst":"Icosagen"},{"author_name":"Anu Planken","author_inst":"Icosagen"},{"author_name":"Kristiina Kurg","author_inst":"Icosagen"},{"author_name":"Eva-Maria Tombak","author_inst":"Icosagen"},{"author_name":"Mart Ustav Jr.","author_inst":"Icosagen"},{"author_name":"Nastassia Shtaida","author_inst":"TUIT"},{"author_name":"Evgeny Kulesskiy","author_inst":"University of Helsinki"},{"author_name":"Eunji Jo","author_inst":"IPK"},{"author_name":"Jaewon Yang","author_inst":"IPK"},{"author_name":"Hilde Lysvand","author_inst":"NTNU"},{"author_name":"Kirsti Loseth","author_inst":"NTNU"},{"author_name":"Valentyn Oksenych","author_inst":"NTNU"},{"author_name":"Per Arne Aas","author_inst":"NTNU"},{"author_name":"Tanel Tenson","author_inst":"University of Tartu"},{"author_name":"Astra Vitkauskiene","author_inst":"LUHS"},{"author_name":"Marc P. Windisch","author_inst":"Institut Pasteur Korea"},{"author_name":"Mona H Fenstad","author_inst":"NTNU"},{"author_name":"Svein Arne Nordbo","author_inst":"NTNU"},{"author_name":"Mart Ustav","author_inst":"Icosagen"},{"author_name":"Magnar Bjoras","author_inst":"NTNU"},{"author_name":"Denis E Kainov","author_inst":"NTNU"},{"author_name":"Wolfgang Herr","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Daniel Wolff","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Hendrik Poeck","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Christoph Brochhausen","author_inst":"Institute of Pathology, Electron Microscopy Unit, University of Regensburg, Germany"},{"author_name":"Petra Hoffmann","author_inst":"Regensburg Center for Interventional Immunology, University of Regensburg, 93053 Regensburg, Germany"},{"author_name":"Michael Rehli","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Marina Kreutz","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"},{"author_name":"Kathrin Renner","author_inst":"Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany"}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"microbiology"},{"rel_doi":"10.1101\/2020.09.17.301093","rel_title":"Comparison of Rhesus and Cynomolgus macaques as an authentic model for COVID-19.","rel_date":"2020-09-17","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.17.301093","rel_abs":"A novel coronavirus, SARS-CoV-2, has been identified as the causative agent of the current COVID-19 pandemic. Animal models, and in particular non-human primates, are essential to understand the pathogenesis of emerging diseases and to the safety and efficacy of novel vaccines and therapeutics. Here, we show that SARS-CoV-2 replicates in the upper and lower respiratory tract and causes pulmonary lesions in both rhesus and cynomolgus macaques, resembling the mild clinical cases of COVID-19 in humans. Immune responses against SARS-CoV-2 were also similar in both species and equivalent to those reported in milder infections and convalescent human patients. Importantly, we have devised a new method for lung histopathology scoring that will provide a metric to enable clearer decision making for this key endpoint. In contrast to prior publications, in which rhesus are accepted to be the optimal study species, we provide convincing evidence that both macaque species authentically represent mild to moderate forms of COVID-19 observed in the majority of the human population and both species should be used to evaluate the safety and efficacy of novel and repurposed interventions against SARS-CoV-2. Accessing cynomolgus macaques will greatly alleviate the pressures on current rhesus stocks.","rel_num_authors":58,"rel_authors":[{"author_name":"Francisco J Salguero","author_inst":"Public Health England"},{"author_name":"Andrew D White","author_inst":"Public Health England"},{"author_name":"Gillian S Slack","author_inst":"Public Health England"},{"author_name":"Susan A Fotheringham","author_inst":"Public Health England"},{"author_name":"Kevin R Bewley","author_inst":"Public Health England"},{"author_name":"Karen E Gooch","author_inst":"Public Health England"},{"author_name":"Stephanie Longet","author_inst":"Public Health England"},{"author_name":"Holly E Humphries","author_inst":"Public Health England"},{"author_name":"Robert J Watson","author_inst":"Public Health England"},{"author_name":"Laura Hunter","author_inst":"Public Health England"},{"author_name":"Kathryn A Ryan","author_inst":"Public Health England"},{"author_name":"Yper Hall","author_inst":"Public Health England"},{"author_name":"Laura Sibley","author_inst":"Public Health England"},{"author_name":"Charlotte Sarfas","author_inst":"Public Health England"},{"author_name":"Lauren Allen","author_inst":"Public Health England"},{"author_name":"Marilyn Aram","author_inst":"Public Health England"},{"author_name":"Emily Brunt","author_inst":"Public Health England"},{"author_name":"Phillip Brown","author_inst":"Public Health England"},{"author_name":"Karen R Buttigieg","author_inst":"Public Health England"},{"author_name":"Breeze E Cavell","author_inst":"Public Health England"},{"author_name":"Rebecca Cobb","author_inst":"Public Health England"},{"author_name":"Naomi S Coombes","author_inst":"Public Health England"},{"author_name":"Owen Daykin-Pont","author_inst":"Public Health England"},{"author_name":"Michael J Elmore","author_inst":"Public Health England"},{"author_name":"Konstantinos Gkolfinos","author_inst":"Public Health England"},{"author_name":"Kerry J Godwin","author_inst":"Public Health England"},{"author_name":"Jade Gouriet","author_inst":"Public Health England"},{"author_name":"Rachel Halkerston","author_inst":"Public Health England"},{"author_name":"Debbie J Harris","author_inst":"Public Health England"},{"author_name":"Thomas Hender","author_inst":"Public Health England"},{"author_name":"Catherine M.K. Ho","author_inst":"Public Health England"},{"author_name":"Chelsea L Kennard","author_inst":"Public Health England"},{"author_name":"Daniel Knott","author_inst":"Public Health England"},{"author_name":"Stephanie Leung","author_inst":"Public Health England"},{"author_name":"Vanessa Lucas","author_inst":"Public Health England"},{"author_name":"Adam Mabbutt","author_inst":"Public Health England"},{"author_name":"Alexandra L Morrison","author_inst":"Public Health England"},{"author_name":"Didier Ngabo","author_inst":"Public Health England"},{"author_name":"Jemma Paterson","author_inst":"Public Health England"},{"author_name":"Elizabeth J Penn","author_inst":"Public Health England"},{"author_name":"Steve Pullan","author_inst":"Public Health England"},{"author_name":"Irene Taylor","author_inst":"Public Health England"},{"author_name":"Tom Tipton","author_inst":"Public Health England"},{"author_name":"Stephen Thomas","author_inst":"Public Health England"},{"author_name":"Julia A Tree","author_inst":"Public Health England"},{"author_name":"Carrie Turner","author_inst":"Public Health England"},{"author_name":"Nadina Wand","author_inst":"Public Health England"},{"author_name":"Nathan R Wiblin","author_inst":"Public Health England"},{"author_name":"Sue Charlton","author_inst":"Public Health England"},{"author_name":"Bassam Hallis","author_inst":"Public Health England"},{"author_name":"Geoffrey Pearson","author_inst":"Public Health England"},{"author_name":"Emma L Rayner","author_inst":"Public Health England"},{"author_name":"Andrew G Nicholson","author_inst":"Public Health England"},{"author_name":"Simon G Funnell","author_inst":"Public Health England"},{"author_name":"Mike J Dennis","author_inst":"Public Health England"},{"author_name":"Fergus V Gleeson","author_inst":"National Heart and Lung Institute"},{"author_name":"Sally Sharpe","author_inst":"Public Health England"},{"author_name":"Miles W Carroll","author_inst":"Public Health England"}],"version":"1","license":"cc_no","type":"new results","category":"microbiology"},{"rel_doi":"10.1101\/2020.09.17.301861","rel_title":"Discovery of human ACE2 variants with altered recognition by the SARS-CoV-2 spike protein","rel_date":"2020-09-17","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.17.301861","rel_abs":"Understanding how human ACE2 genetic variants differ in their recognition by SARS-CoV-2 can have a major impact in leveraging ACE2 as an axis for treating and preventing COVID-19. In this work, we experimentally interrogate thousands of ACE2 mutants to identify over one hundred human single-nucleotide variants (SNVs) that are likely to have altered recognition by the virus, and make the complementary discovery that ACE2 residues distant from the spike interface can have a strong influence upon the ACE2-spike interaction. These findings illuminate new links between ACE2 sequence and spike recognition, and will find wide-ranging utility in SARS-CoV-2 fundamental research, epidemiological analyses, and clinical trial design.","rel_num_authors":2,"rel_authors":[{"author_name":"Pete Heinzelman","author_inst":"University of Wisconsin--Madison"},{"author_name":"Philip A Romero","author_inst":"University of Wisconsin--Madison"},{"author_name":"Gillian S Slack","author_inst":"Public Health England"},{"author_name":"Susan A Fotheringham","author_inst":"Public Health England"},{"author_name":"Kevin R Bewley","author_inst":"Public Health England"},{"author_name":"Karen E Gooch","author_inst":"Public Health England"},{"author_name":"Stephanie Longet","author_inst":"Public Health England"},{"author_name":"Holly E Humphries","author_inst":"Public Health England"},{"author_name":"Robert J Watson","author_inst":"Public Health England"},{"author_name":"Laura Hunter","author_inst":"Public Health England"},{"author_name":"Kathryn A Ryan","author_inst":"Public Health England"},{"author_name":"Yper Hall","author_inst":"Public Health England"},{"author_name":"Laura Sibley","author_inst":"Public Health England"},{"author_name":"Charlotte Sarfas","author_inst":"Public Health England"},{"author_name":"Lauren Allen","author_inst":"Public Health England"},{"author_name":"Marilyn Aram","author_inst":"Public Health England"},{"author_name":"Emily Brunt","author_inst":"Public Health England"},{"author_name":"Phillip Brown","author_inst":"Public Health England"},{"author_name":"Karen R Buttigieg","author_inst":"Public Health England"},{"author_name":"Breeze E Cavell","author_inst":"Public Health England"},{"author_name":"Rebecca Cobb","author_inst":"Public Health England"},{"author_name":"Naomi S Coombes","author_inst":"Public Health England"},{"author_name":"Owen Daykin-Pont","author_inst":"Public Health England"},{"author_name":"Michael J Elmore","author_inst":"Public Health England"},{"author_name":"Konstantinos Gkolfinos","author_inst":"Public Health England"},{"author_name":"Kerry J Godwin","author_inst":"Public Health England"},{"author_name":"Jade Gouriet","author_inst":"Public Health England"},{"author_name":"Rachel Halkerston","author_inst":"Public Health England"},{"author_name":"Debbie J Harris","author_inst":"Public Health England"},{"author_name":"Thomas Hender","author_inst":"Public Health England"},{"author_name":"Catherine M.K. Ho","author_inst":"Public Health England"},{"author_name":"Chelsea L Kennard","author_inst":"Public Health England"},{"author_name":"Daniel Knott","author_inst":"Public Health England"},{"author_name":"Stephanie Leung","author_inst":"Public Health England"},{"author_name":"Vanessa Lucas","author_inst":"Public Health England"},{"author_name":"Adam Mabbutt","author_inst":"Public Health England"},{"author_name":"Alexandra L Morrison","author_inst":"Public Health England"},{"author_name":"Didier Ngabo","author_inst":"Public Health England"},{"author_name":"Jemma Paterson","author_inst":"Public Health England"},{"author_name":"Elizabeth J Penn","author_inst":"Public Health England"},{"author_name":"Steve Pullan","author_inst":"Public Health England"},{"author_name":"Irene Taylor","author_inst":"Public Health England"},{"author_name":"Tom Tipton","author_inst":"Public Health England"},{"author_name":"Stephen Thomas","author_inst":"Public Health England"},{"author_name":"Julia A Tree","author_inst":"Public Health England"},{"author_name":"Carrie Turner","author_inst":"Public Health England"},{"author_name":"Nadina Wand","author_inst":"Public Health England"},{"author_name":"Nathan R Wiblin","author_inst":"Public Health England"},{"author_name":"Sue Charlton","author_inst":"Public Health England"},{"author_name":"Bassam Hallis","author_inst":"Public Health England"},{"author_name":"Geoffrey Pearson","author_inst":"Public Health England"},{"author_name":"Emma L Rayner","author_inst":"Public Health England"},{"author_name":"Andrew G Nicholson","author_inst":"Public Health England"},{"author_name":"Simon G Funnell","author_inst":"Public Health England"},{"author_name":"Mike J Dennis","author_inst":"Public Health England"},{"author_name":"Fergus V Gleeson","author_inst":"National Heart and Lung Institute"},{"author_name":"Sally Sharpe","author_inst":"Public Health England"},{"author_name":"Miles W Carroll","author_inst":"Public Health England"}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"genetics"},{"rel_doi":"10.1101\/2020.09.17.302380","rel_title":"Topography, spike dynamics and nanomechanics of individual native SARS-CoV-2 virions","rel_date":"2020-09-17","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.17.302380","rel_abs":"SARS-CoV-2, the virus responsible for the current COVID-19 pandemic, displays a corona-shaped layer of spikes which play fundamental role in the infection process. Recent structural data suggest that the spikes possess orientational freedom and the ribonucleoproteins segregate into basketlike structures. How these structural features regulate the dynamic and mechanical behavior of the native virion, however, remain unknown. By imaging and mechanically manipulating individual, native SARS-CoV-2 virions with atomic force microscopy, here we show that their surface displays a dynamic brush owing to the flexibility and rapid motion of the spikes. The virions are highly compliant and able to recover from drastic mechanical perturbations. Their global structure is remarkably temperature resistant, but the virion surface becomes progressively denuded of spikes upon thermal exposure. Thus, both the infectivity and thermal sensitivity of SARS-CoV-2 rely on the dynamics and the mechanics of the virus.\n\nOne sentence summaryThe native coronavirus 2 displays a dynamic surface layer of spikes, a large mechanical compliance and unique self-healing capacity.","rel_num_authors":4,"rel_authors":[{"author_name":"Balint Kiss","author_inst":"Semmelweis University"},{"author_name":"Zoltan Kis","author_inst":"National Public Health Center"},{"author_name":"Bernadett Palyi","author_inst":"National Public Health Center"},{"author_name":"Miklos Kellermayer","author_inst":"Semmelweis University"},{"author_name":"Kevin R Bewley","author_inst":"Public Health England"},{"author_name":"Karen E Gooch","author_inst":"Public Health England"},{"author_name":"Stephanie Longet","author_inst":"Public Health England"},{"author_name":"Holly E Humphries","author_inst":"Public Health England"},{"author_name":"Robert J Watson","author_inst":"Public Health England"},{"author_name":"Laura Hunter","author_inst":"Public Health England"},{"author_name":"Kathryn A Ryan","author_inst":"Public Health England"},{"author_name":"Yper Hall","author_inst":"Public Health England"},{"author_name":"Laura Sibley","author_inst":"Public Health England"},{"author_name":"Charlotte Sarfas","author_inst":"Public Health England"},{"author_name":"Lauren Allen","author_inst":"Public Health England"},{"author_name":"Marilyn Aram","author_inst":"Public Health England"},{"author_name":"Emily Brunt","author_inst":"Public Health England"},{"author_name":"Phillip Brown","author_inst":"Public Health England"},{"author_name":"Karen R Buttigieg","author_inst":"Public Health England"},{"author_name":"Breeze E Cavell","author_inst":"Public Health England"},{"author_name":"Rebecca Cobb","author_inst":"Public Health England"},{"author_name":"Naomi S Coombes","author_inst":"Public Health England"},{"author_name":"Owen Daykin-Pont","author_inst":"Public Health England"},{"author_name":"Michael J Elmore","author_inst":"Public Health England"},{"author_name":"Konstantinos Gkolfinos","author_inst":"Public Health England"},{"author_name":"Kerry J Godwin","author_inst":"Public Health England"},{"author_name":"Jade Gouriet","author_inst":"Public Health England"},{"author_name":"Rachel Halkerston","author_inst":"Public Health England"},{"author_name":"Debbie J Harris","author_inst":"Public Health England"},{"author_name":"Thomas Hender","author_inst":"Public Health England"},{"author_name":"Catherine M.K. Ho","author_inst":"Public Health England"},{"author_name":"Chelsea L Kennard","author_inst":"Public Health England"},{"author_name":"Daniel Knott","author_inst":"Public Health England"},{"author_name":"Stephanie Leung","author_inst":"Public Health England"},{"author_name":"Vanessa Lucas","author_inst":"Public Health England"},{"author_name":"Adam Mabbutt","author_inst":"Public Health England"},{"author_name":"Alexandra L Morrison","author_inst":"Public Health England"},{"author_name":"Didier Ngabo","author_inst":"Public Health England"},{"author_name":"Jemma Paterson","author_inst":"Public Health England"},{"author_name":"Elizabeth J Penn","author_inst":"Public Health England"},{"author_name":"Steve Pullan","author_inst":"Public Health England"},{"author_name":"Irene Taylor","author_inst":"Public Health England"},{"author_name":"Tom Tipton","author_inst":"Public Health England"},{"author_name":"Stephen Thomas","author_inst":"Public Health England"},{"author_name":"Julia A Tree","author_inst":"Public Health England"},{"author_name":"Carrie Turner","author_inst":"Public Health England"},{"author_name":"Nadina Wand","author_inst":"Public Health England"},{"author_name":"Nathan R Wiblin","author_inst":"Public Health England"},{"author_name":"Sue Charlton","author_inst":"Public Health England"},{"author_name":"Bassam Hallis","author_inst":"Public Health England"},{"author_name":"Geoffrey Pearson","author_inst":"Public Health England"},{"author_name":"Emma L Rayner","author_inst":"Public Health England"},{"author_name":"Andrew G Nicholson","author_inst":"Public Health England"},{"author_name":"Simon G Funnell","author_inst":"Public Health England"},{"author_name":"Mike J Dennis","author_inst":"Public Health England"},{"author_name":"Fergus V Gleeson","author_inst":"National Heart and Lung Institute"},{"author_name":"Sally Sharpe","author_inst":"Public Health England"},{"author_name":"Miles W Carroll","author_inst":"Public Health England"}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"biophysics"},{"rel_doi":"10.1101\/2020.09.17.300335","rel_title":"Structural and Functional Comparison of SARS-CoV-2-Spike Receptor Binding Domain Produced in Pichia pastoris and Mammalian Cells","rel_date":"2020-09-17","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.17.300335","rel_abs":"The yeast Pichia pastoris is a cost-effective and easily scalable system for recombinant protein production. In this work we compared the conformation of the receptor binding domain (RBD) from SARS-CoV-2 Spike protein expressed in P. pastoris and in the well established HEK-293T mammalian cell system. RBD obtained from both yeast and mammalian cells was properly folded, as indicated by UV-absorption, circular dichroism and tryptophan fluorescence. They also had similar stability, as indicated by temperature-induced unfolding (observed Tm were 50 {degrees}C and 52 {degrees}C for RBD produced in P. pastoris and HEK-293T cells, respectively). Moreover, the stability of both variants was similarly reduced when the ionic strength was increased, in agreement with a computational analysis predicting that a set of ionic interactions may stabilize RBD structure. Further characterization by HPLC, size-exclusion chromatography and mass spectrometry revealed a higher heterogeneity of RBD expressed in P. pastoris relative to that produced in HEK-293T cells, which disappeared after enzymatic removal of glycans. The production of RBD in P. pastoris was scaled-up in a bioreactor, with yields above 45 mg\/L of 90% pure protein, thus potentially allowing large scale immunizations to produce neutralizing antibodies, as well as the large scale production of serological tests for SARS-CoV-2.","rel_num_authors":30,"rel_authors":[{"author_name":"- Argentinian AntiCovid Consortium","author_inst":"-"},{"author_name":"Claudia R. Arbeitman","author_inst":"Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET). Godoy Cruz 2290 C1425FQB, Buenos Aires, Argentina."},{"author_name":"Gabriela Auge","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Matias Blaustein","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Luis Bredeston","author_inst":"Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Quimica Biologica. Junin 965 C1113AAD. Buenos Aires, Argentina."},{"author_name":"Enrique S. Corapi","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Patricio O. Craig","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Quimica Biologica. Buenos Aires, Argentina."},{"author_name":"Leandro A. Cossio","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Laboratorio de Agrobiotecnolog"},{"author_name":"Liliana Dain","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Buenos Aires, Argentina. Centr"},{"author_name":"Fernanda Elias","author_inst":"Instituto de Ciencia y Tecnologia Dr. Cesar Milstein (Consejo Nacional de Investigaciones Cientificas y Tecnicas-Fundacion Pablo Cassara). Saladillo 2468 (C1440"},{"author_name":"Natalia B. Fernandez","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Javier Gasulla","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Natalia Gorojovsky","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Quimica Biologica. Buenos Aires, Argentina."},{"author_name":"Gustavo E. Gudesblat","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Maria G. Herrera","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Lorena I. Iba\u00f1ez","author_inst":"Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET). Instituto de Ciencia y Tecnologia Dr. Cesar Milstein, Saladillo 2468, C1440FFX Buenos Aire"},{"author_name":"Tommy Idrovo","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Matias Iglesias Rando","author_inst":"Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Quimica Biologica. Junin 965 C1113AAD, Buenos Aires, Argentina."},{"author_name":"Laura Kamenetzky","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Alejandro D Nadra","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Diego G. Noseda","author_inst":"Universidad Nacional de San Martin - CONICET. Instituto de Investigaciones Biotecnologicas (IIBio). San Martin, Buenos Aires, Argentina."},{"author_name":"Carlos H. Pavan","author_inst":"Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica. Buenos Aires, Argentina."},{"author_name":"Maria F. Pavan","author_inst":"Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET). Instituto de Ciencia y Tecnologia Dr. Cesar Milstein, Saladillo 2468, C1440FFX Buenos Aire"},{"author_name":"Maria F. Pignataro","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Ernesto Roman","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Quimica Biologica. Buenos Aires, Argentina."},{"author_name":"Lucas A.M Ruberto","author_inst":"Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Microbiologia, Inmunologia, Biotecnologia y Genetica. Buenos Aires, Argentina."},{"author_name":"Natalia Rubinstein","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Javier Santos","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Francisco Velazquez","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Alicia M. Zelada","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Laboratorio de Agrobiotecnolog"},{"author_name":"Catherine M.K. Ho","author_inst":"Public Health England"},{"author_name":"Chelsea L Kennard","author_inst":"Public Health England"},{"author_name":"Daniel Knott","author_inst":"Public Health England"},{"author_name":"Stephanie Leung","author_inst":"Public Health England"},{"author_name":"Vanessa Lucas","author_inst":"Public Health England"},{"author_name":"Adam Mabbutt","author_inst":"Public Health England"},{"author_name":"Alexandra L Morrison","author_inst":"Public Health England"},{"author_name":"Didier Ngabo","author_inst":"Public Health England"},{"author_name":"Jemma Paterson","author_inst":"Public Health England"},{"author_name":"Elizabeth J Penn","author_inst":"Public Health England"},{"author_name":"Steve Pullan","author_inst":"Public Health England"},{"author_name":"Irene Taylor","author_inst":"Public Health England"},{"author_name":"Tom Tipton","author_inst":"Public Health England"},{"author_name":"Stephen Thomas","author_inst":"Public Health England"},{"author_name":"Julia A Tree","author_inst":"Public Health England"},{"author_name":"Carrie Turner","author_inst":"Public Health England"},{"author_name":"Nadina Wand","author_inst":"Public Health England"},{"author_name":"Nathan R Wiblin","author_inst":"Public Health England"},{"author_name":"Sue Charlton","author_inst":"Public Health England"},{"author_name":"Bassam Hallis","author_inst":"Public Health England"},{"author_name":"Geoffrey Pearson","author_inst":"Public Health England"},{"author_name":"Emma L Rayner","author_inst":"Public Health England"},{"author_name":"Andrew G Nicholson","author_inst":"Public Health England"},{"author_name":"Simon G Funnell","author_inst":"Public Health England"},{"author_name":"Mike J Dennis","author_inst":"Public Health England"},{"author_name":"Fergus V Gleeson","author_inst":"National Heart and Lung Institute"},{"author_name":"Sally Sharpe","author_inst":"Public Health England"},{"author_name":"Miles W Carroll","author_inst":"Public Health England"}],"version":"1","license":"cc_by","type":"new results","category":"biochemistry"},{"rel_doi":"10.1101\/2020.09.17.302232","rel_title":"Fixed single-cell RNA sequencing for understanding virus infection and host response","rel_date":"2020-09-17","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.17.302232","rel_abs":"Single-cell RNA sequencing studies requiring intracellular protein staining, rare-cell sorting, or pathogen inactivation are severely limited because current high-throughput methods are incompatible with paraformaldehyde treatment, a very common and simple tissue\/cell fixation and preservation technique. Here we present FD-seq, a high-throughput method for droplet-based RNA sequencing of paraformaldehyde-fixed, stained and sorted single-cells. We used FD-seq to address two important questions in virology. First, by analyzing a rare population of cells supporting lytic reactivation of the human tumor virus KSHV, we identified TMEM119 as a host factor that mediates reactivation. Second, we studied the transcriptome of lung cells infected with the coronavirus OC43, which causes the common cold and also serves as a safer model pathogen for SARS-CoV-2. We found that pro-inflammatory pathways are primarily upregulated in abortively-infected or uninfected bystander cells, which are exposed to the virus but fail to express high level of viral genes. FD-seq is suitable for characterizing rare cell populations of interest, for studying high-containment biological samples after inactivation, and for integrating intracellular phenotypic with transcriptomic information.","rel_num_authors":6,"rel_authors":[{"author_name":"Hoang Van Phan","author_inst":"The University of Chicago"},{"author_name":"Michiel van Gent","author_inst":"Cleveland Clinic Florida Research and Innovation Center"},{"author_name":"Nir Drayman","author_inst":"University of Chicago"},{"author_name":"Anindita Basu","author_inst":"Univaersity of Chicago"},{"author_name":"Michaela Gack","author_inst":"Cleveland Clinic Florida Research and Innovation Center"},{"author_name":"Savas Tay","author_inst":"The University of Chicago"},{"author_name":"Patricio O. Craig","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Quimica Biologica. Buenos Aires, Argentina."},{"author_name":"Leandro A. Cossio","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Laboratorio de Agrobiotecnolog"},{"author_name":"Liliana Dain","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Buenos Aires, Argentina. Centr"},{"author_name":"Fernanda Elias","author_inst":"Instituto de Ciencia y Tecnologia Dr. Cesar Milstein (Consejo Nacional de Investigaciones Cientificas y Tecnicas-Fundacion Pablo Cassara). Saladillo 2468 (C1440"},{"author_name":"Natalia B. Fernandez","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Javier Gasulla","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Natalia Gorojovsky","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Quimica Biologica. Buenos Aires, Argentina."},{"author_name":"Gustavo E. Gudesblat","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Maria G. Herrera","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Lorena I. Iba\u00f1ez","author_inst":"Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET). Instituto de Ciencia y Tecnologia Dr. Cesar Milstein, Saladillo 2468, C1440FFX Buenos Aire"},{"author_name":"Tommy Idrovo","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Matias Iglesias Rando","author_inst":"Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Quimica Biologica. Junin 965 C1113AAD, Buenos Aires, Argentina."},{"author_name":"Laura Kamenetzky","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Alejandro D Nadra","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Diego G. Noseda","author_inst":"Universidad Nacional de San Martin - CONICET. Instituto de Investigaciones Biotecnologicas (IIBio). San Martin, Buenos Aires, Argentina."},{"author_name":"Carlos H. Pavan","author_inst":"Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica. Buenos Aires, Argentina."},{"author_name":"Maria F. Pavan","author_inst":"Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET). Instituto de Ciencia y Tecnologia Dr. Cesar Milstein, Saladillo 2468, C1440FFX Buenos Aire"},{"author_name":"Maria F. Pignataro","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Ernesto Roman","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Quimica Biologica. Buenos Aires, Argentina."},{"author_name":"Lucas A.M Ruberto","author_inst":"Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Microbiologia, Inmunologia, Biotecnologia y Genetica. Buenos Aires, Argentina."},{"author_name":"Natalia Rubinstein","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Javier Santos","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Francisco Velazquez","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Alicia M. Zelada","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Laboratorio de Agrobiotecnolog"},{"author_name":"Catherine M.K. Ho","author_inst":"Public Health England"},{"author_name":"Chelsea L Kennard","author_inst":"Public Health England"},{"author_name":"Daniel Knott","author_inst":"Public Health England"},{"author_name":"Stephanie Leung","author_inst":"Public Health England"},{"author_name":"Vanessa Lucas","author_inst":"Public Health England"},{"author_name":"Adam Mabbutt","author_inst":"Public Health England"},{"author_name":"Alexandra L Morrison","author_inst":"Public Health England"},{"author_name":"Didier Ngabo","author_inst":"Public Health England"},{"author_name":"Jemma Paterson","author_inst":"Public Health England"},{"author_name":"Elizabeth J Penn","author_inst":"Public Health England"},{"author_name":"Steve Pullan","author_inst":"Public Health England"},{"author_name":"Irene Taylor","author_inst":"Public Health England"},{"author_name":"Tom Tipton","author_inst":"Public Health England"},{"author_name":"Stephen Thomas","author_inst":"Public Health England"},{"author_name":"Julia A Tree","author_inst":"Public Health England"},{"author_name":"Carrie Turner","author_inst":"Public Health England"},{"author_name":"Nadina Wand","author_inst":"Public Health England"},{"author_name":"Nathan R Wiblin","author_inst":"Public Health England"},{"author_name":"Sue Charlton","author_inst":"Public Health England"},{"author_name":"Bassam Hallis","author_inst":"Public Health England"},{"author_name":"Geoffrey Pearson","author_inst":"Public Health England"},{"author_name":"Emma L Rayner","author_inst":"Public Health England"},{"author_name":"Andrew G Nicholson","author_inst":"Public Health England"},{"author_name":"Simon G Funnell","author_inst":"Public Health England"},{"author_name":"Mike J Dennis","author_inst":"Public Health England"},{"author_name":"Fergus V Gleeson","author_inst":"National Heart and Lung Institute"},{"author_name":"Sally Sharpe","author_inst":"Public Health England"},{"author_name":"Miles W Carroll","author_inst":"Public Health England"}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"genomics"},{"rel_doi":"10.1101\/2020.09.17.301614","rel_title":"Mutational signatures in countries affected by SARS-CoV-2: Implications in host-pathogen interactome","rel_date":"2020-09-17","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.17.301614","rel_abs":"We are in the midst of the third severe coronavirus outbreak caused by SARS-CoV-2 with unprecedented health and socio-economic consequences due to the COVID-19. Globally, the major thrust of scientific efforts has shifted to the design of potent vaccine and anti-viral candidates. Earlier genome analyses have shown global dominance of some mutations purportedly indicative of similar infectivity and transmissibility of SARS-CoV-2 worldwide. Using high-quality large dataset of 25k whole-genome sequences, we show emergence of new cluster of mutations as result of geographic evolution of SARS-CoV-2 in local population ([&ge;]10%) of different nations. Using statistical analysis, we observe that these mutations have either significantly co-occurred in globally dominant strains or have shown mutual exclusivity in other cases. These mutations potentially modulate structural stability of proteins, some of which forms part of SARS-CoV-2-human interactome. The high confidence druggable host proteins are also up-regulated during SARS-CoV-2 infection. Mutations occurring in potential hot-spot regions within likely T-cell and B-cell epitopes or in proteins as part of host-viral interactome, could hamper vaccine or drug efficacy in local population. Overall, our study provides comprehensive view of emerging geo-clonal mutations which would aid researchers to understand and develop effective countermeasures in the current crisis.\n\nSignificanceOur comparative analysis of globally dominant mutations and region-specific mutations in 25k SARS-CoV-2 genomes elucidates its geo-clonal evolution. We observe locally dominant mutations (co-occurring or mutually exclusive) in nations with contrasting COVID-19 mortalities per million of population) besides globally dominant ones namely, P314L (ORF1b) and D164G (S) type. We also see exclusive dominant mutations such as in Brazil (I33T in ORF6 and I292T in N protein), England (G251V in ORF3a), India (T2016K and L3606F in ORF1a) and in Spain (L84S in ORF8). The emergence of these local mutations in ORFs within SARS-CoV-2 genome could have interventional implications and also points towards their potential in modulating infectivity of SARS-CoV-2 in regional population.","rel_num_authors":3,"rel_authors":[{"author_name":"Syed Asad Rahman","author_inst":"BioInception Pvt. Ltd"},{"author_name":"Jasdeep Singh","author_inst":"Institute of Molecular Medicine Jamia Hamdard, India"},{"author_name":"Hina Singh","author_inst":"Institute of Molecular Medicine, Jamia Hamdard, India"},{"author_name":"Anindita Basu","author_inst":"Univaersity of Chicago"},{"author_name":"Michaela Gack","author_inst":"Cleveland Clinic Florida Research and Innovation Center"},{"author_name":"Savas Tay","author_inst":"The University of Chicago"},{"author_name":"Patricio O. Craig","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Quimica Biologica. Buenos Aires, Argentina."},{"author_name":"Leandro A. Cossio","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Laboratorio de Agrobiotecnolog"},{"author_name":"Liliana Dain","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Buenos Aires, Argentina. Centr"},{"author_name":"Fernanda Elias","author_inst":"Instituto de Ciencia y Tecnologia Dr. Cesar Milstein (Consejo Nacional de Investigaciones Cientificas y Tecnicas-Fundacion Pablo Cassara). Saladillo 2468 (C1440"},{"author_name":"Natalia B. Fernandez","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Javier Gasulla","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Natalia Gorojovsky","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Quimica Biologica. Buenos Aires, Argentina."},{"author_name":"Gustavo E. Gudesblat","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Maria G. Herrera","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Lorena I. Iba\u00f1ez","author_inst":"Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET). Instituto de Ciencia y Tecnologia Dr. Cesar Milstein, Saladillo 2468, C1440FFX Buenos Aire"},{"author_name":"Tommy Idrovo","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Matias Iglesias Rando","author_inst":"Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Quimica Biologica. Junin 965 C1113AAD, Buenos Aires, Argentina."},{"author_name":"Laura Kamenetzky","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Alejandro D Nadra","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Diego G. Noseda","author_inst":"Universidad Nacional de San Martin - CONICET. Instituto de Investigaciones Biotecnologicas (IIBio). San Martin, Buenos Aires, Argentina."},{"author_name":"Carlos H. Pavan","author_inst":"Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica. Buenos Aires, Argentina."},{"author_name":"Maria F. Pavan","author_inst":"Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET). Instituto de Ciencia y Tecnologia Dr. Cesar Milstein, Saladillo 2468, C1440FFX Buenos Aire"},{"author_name":"Maria F. Pignataro","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Ernesto Roman","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Quimica Biologica. Buenos Aires, Argentina."},{"author_name":"Lucas A.M Ruberto","author_inst":"Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Microbiologia, Inmunologia, Biotecnologia y Genetica. Buenos Aires, Argentina."},{"author_name":"Natalia Rubinstein","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Javier Santos","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Francisco Velazquez","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Alicia M. Zelada","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Laboratorio de Agrobiotecnolog"},{"author_name":"Catherine M.K. Ho","author_inst":"Public Health England"},{"author_name":"Chelsea L Kennard","author_inst":"Public Health England"},{"author_name":"Daniel Knott","author_inst":"Public Health England"},{"author_name":"Stephanie Leung","author_inst":"Public Health England"},{"author_name":"Vanessa Lucas","author_inst":"Public Health England"},{"author_name":"Adam Mabbutt","author_inst":"Public Health England"},{"author_name":"Alexandra L Morrison","author_inst":"Public Health England"},{"author_name":"Didier Ngabo","author_inst":"Public Health England"},{"author_name":"Jemma Paterson","author_inst":"Public Health England"},{"author_name":"Elizabeth J Penn","author_inst":"Public Health England"},{"author_name":"Steve Pullan","author_inst":"Public Health England"},{"author_name":"Irene Taylor","author_inst":"Public Health England"},{"author_name":"Tom Tipton","author_inst":"Public Health England"},{"author_name":"Stephen Thomas","author_inst":"Public Health England"},{"author_name":"Julia A Tree","author_inst":"Public Health England"},{"author_name":"Carrie Turner","author_inst":"Public Health England"},{"author_name":"Nadina Wand","author_inst":"Public Health England"},{"author_name":"Nathan R Wiblin","author_inst":"Public Health England"},{"author_name":"Sue Charlton","author_inst":"Public Health England"},{"author_name":"Bassam Hallis","author_inst":"Public Health England"},{"author_name":"Geoffrey Pearson","author_inst":"Public Health England"},{"author_name":"Emma L Rayner","author_inst":"Public Health England"},{"author_name":"Andrew G Nicholson","author_inst":"Public Health England"},{"author_name":"Simon G Funnell","author_inst":"Public Health England"},{"author_name":"Mike J Dennis","author_inst":"Public Health England"},{"author_name":"Fergus V Gleeson","author_inst":"National Heart and Lung Institute"},{"author_name":"Sally Sharpe","author_inst":"Public Health England"},{"author_name":"Miles W Carroll","author_inst":"Public Health England"}],"version":"1","license":"cc_no","type":"new results","category":"bioinformatics"},{"rel_doi":"10.1101\/2020.09.16.300459","rel_title":"The flexibility of ACE2 in the context of SARS-CoV-2 infection","rel_date":"2020-09-16","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.16.300459","rel_abs":"The COVID-19 pandemic has swept over the world in the past months, causing significant loss of life and consequences to human health. Although numerous drug and vaccine developments efforts are underway, many questions remain outstanding on the mechanism of SARS-CoV-2 viral association to angiotensin-converting enzyme 2 (ACE2), its main host receptor, and entry in the cell. Structural and biophysical studies indicate some degree of flexibility in the viral extracellular Spike glycoprotein and at the receptor binding domain-receptor interface, suggesting a role in infection. Here, we perform all-atom molecular dynamics simulations of the glycosylated, full-length membrane-bound ACE2 receptor, in both an apo and spike receptor binding domain (RBD) bound state, in order to probe the intrinsic dynamics of the ACE2 receptor in the context of the cell surface. A large degree of fluctuation in the full length structure is observed, indicating hinge bending motions at the linker region connecting the head to the transmembrane helix, while still not disrupting the ACE2 homodimer or ACE2-RBD interfaces. This flexibility translates into an ensemble of ACE2 homodimer conformations that could sterically accommodate binding of the spike trimer to more than one ACE2 homodimer, and suggests a mechanical contribution of the host receptor towards the large spike conformational changes required for cell fusion. This work presents further structural and functional insights into the role of ACE2 in viral infection that can be exploited for the rational design of effective SARS-CoV-2 therapeutics.\n\nStatement of SignificanceAs the host receptor of SARS-CoV-2, ACE2 has been the subject of extensive structural and antibody design efforts in aims to curtail COVID-19 spread. Here, we perform molecular dynamics simulations of the homodimer ACE2 full-length structure to study the dynamics of this protein in the context of the cellular membrane. The simulations evidence exceptional plasticity in the protein structure due to flexible hinge motions in the head-transmembrane domain linker region and helix mobility in the membrane, resulting in a varied ensemble of conformations distinct from the experimental structures. Our findings suggest a dynamical contribution of ACE2 to the spike glycoprotein shedding required for infection, and contribute to the question of stoichiometry of the Spike-ACE2 complex.","rel_num_authors":10,"rel_authors":[{"author_name":"Emilia P. Barros","author_inst":"University of California, San Diego"},{"author_name":"Lorenzo Casalino","author_inst":"University of California San Diego"},{"author_name":"Zied Gaieb","author_inst":"University of California, San Diego"},{"author_name":"Abigail C Dommer","author_inst":"UC San Diego"},{"author_name":"Yuzhang Wang","author_inst":"State University of New York"},{"author_name":"Lucy Fallon","author_inst":"State University of New York"},{"author_name":"Lauren Raguette","author_inst":"State University of New York"},{"author_name":"Kellon Belfon","author_inst":"State University of New York"},{"author_name":"Carlos L. Simmerling","author_inst":"SUNY at Stony Brook"},{"author_name":"Rommie E. Amaro","author_inst":"UC San Diego"},{"author_name":"Natalia B. Fernandez","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Javier Gasulla","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Natalia Gorojovsky","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Quimica Biologica. Buenos Aires, Argentina."},{"author_name":"Gustavo E. Gudesblat","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Maria G. Herrera","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Lorena I. Iba\u00f1ez","author_inst":"Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET). Instituto de Ciencia y Tecnologia Dr. Cesar Milstein, Saladillo 2468, C1440FFX Buenos Aire"},{"author_name":"Tommy Idrovo","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Matias Iglesias Rando","author_inst":"Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Quimica Biologica. Junin 965 C1113AAD, Buenos Aires, Argentina."},{"author_name":"Laura Kamenetzky","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Alejandro D Nadra","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Diego G. Noseda","author_inst":"Universidad Nacional de San Martin - CONICET. Instituto de Investigaciones Biotecnologicas (IIBio). San Martin, Buenos Aires, Argentina."},{"author_name":"Carlos H. Pavan","author_inst":"Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica. Buenos Aires, Argentina."},{"author_name":"Maria F. Pavan","author_inst":"Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET). Instituto de Ciencia y Tecnologia Dr. Cesar Milstein, Saladillo 2468, C1440FFX Buenos Aire"},{"author_name":"Maria F. Pignataro","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Ernesto Roman","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Quimica Biologica. Buenos Aires, Argentina."},{"author_name":"Lucas A.M Ruberto","author_inst":"Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Microbiologia, Inmunologia, Biotecnologia y Genetica. Buenos Aires, Argentina."},{"author_name":"Natalia Rubinstein","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Javier Santos","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Francisco Velazquez","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Alicia M. Zelada","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Laboratorio de Agrobiotecnolog"},{"author_name":"Catherine M.K. Ho","author_inst":"Public Health England"},{"author_name":"Chelsea L Kennard","author_inst":"Public Health England"},{"author_name":"Daniel Knott","author_inst":"Public Health England"},{"author_name":"Stephanie Leung","author_inst":"Public Health England"},{"author_name":"Vanessa Lucas","author_inst":"Public Health England"},{"author_name":"Adam Mabbutt","author_inst":"Public Health England"},{"author_name":"Alexandra L Morrison","author_inst":"Public Health England"},{"author_name":"Didier Ngabo","author_inst":"Public Health England"},{"author_name":"Jemma Paterson","author_inst":"Public Health England"},{"author_name":"Elizabeth J Penn","author_inst":"Public Health England"},{"author_name":"Steve Pullan","author_inst":"Public Health England"},{"author_name":"Irene Taylor","author_inst":"Public Health England"},{"author_name":"Tom Tipton","author_inst":"Public Health England"},{"author_name":"Stephen Thomas","author_inst":"Public Health England"},{"author_name":"Julia A Tree","author_inst":"Public Health England"},{"author_name":"Carrie Turner","author_inst":"Public Health England"},{"author_name":"Nadina Wand","author_inst":"Public Health England"},{"author_name":"Nathan R Wiblin","author_inst":"Public Health England"},{"author_name":"Sue Charlton","author_inst":"Public Health England"},{"author_name":"Bassam Hallis","author_inst":"Public Health England"},{"author_name":"Geoffrey Pearson","author_inst":"Public Health England"},{"author_name":"Emma L Rayner","author_inst":"Public Health England"},{"author_name":"Andrew G Nicholson","author_inst":"Public Health England"},{"author_name":"Simon G Funnell","author_inst":"Public Health England"},{"author_name":"Mike J Dennis","author_inst":"Public Health England"},{"author_name":"Fergus V Gleeson","author_inst":"National Heart and Lung Institute"},{"author_name":"Sally Sharpe","author_inst":"Public Health England"},{"author_name":"Miles W Carroll","author_inst":"Public Health England"}],"version":"1","license":"cc_by","type":"new results","category":"biophysics"},{"rel_doi":"10.1101\/2020.09.16.299537","rel_title":"Mouse model for testing SARS-CoV-2 antivirals: Pharmacokinetics","rel_date":"2020-09-16","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.16.299537","rel_abs":"Background and ObjectivesRemdesivir and hydroxychloroquine are or were among the most promising therapeutic options to tackle the current SARS-CoV-2 pandemic. Besides the use of the prodrug remdesivir itself, the direct administration of GS-441 524, the resulting main metabolite of remdesivir, could be advantageous and even more effective. All substances were not originally developed for the treatment of COVID-19 and especially for GS-441 524 little is known about its pharmacokinetic and physical-chemical properties. To justify the application of new or repurposed drugs in humans, pre-clinical in vivo animal models are mandatory to investigate relevant PK and PD properties and their relationship to each other. In this study, an adapted mouse model was chosen to demonstrate its suitability to provide sufficient information on the model substances GS-441 524 and HCQ regarding plasma concentration and distribution into relevant tissues a prerequisite for treatment effectiveness.\n\nMethodsGS-441 524 and HCQ were administered intravenously as a single injection to male mice. Blood and organ samples were taken at several time points and drug concentrations were quantified in plasma and tissue homogenates by two liquid chromatography\/tandem mass spectrometry methods. In vitro experiments were conducted to investigate the degradation of remdesivir in human plasma and blood. All pharmacokinetic analyses were performed with R Studio using non-compartmental analysis.\n\nResultsHigh tissue to plasma ratios for GS-441 524 and HCQ were found, indicating a significant distribution into the examined tissue, except for the central nervous system and fat. For GS-441 524, measured tissue concentrations exceeded the reported in vitro EC50 values by more than 10-fold and in consideration of its high efficacy against feline infectious peritonitis, GS-441 524 could indeed be effective against SARS-CoV-2 in vivo. For HCQ, relatively high in vitro EC50 values are reported, which were not reached in all tissues. Facing its slow tissue distribution, HCQ might not lead to sufficient tissue saturation for a reliable antiviral effect.\n\nConclusionThe mouse model was able to characterise the PK and tissue distribution of both model substances and is a suitable tool to investigate early drug candidates against SARS-CoV-2. Furthermore, we could demonstrate a high tissue distribution of GS-441 524 even if not administered as the prodrug remdesivir.","rel_num_authors":11,"rel_authors":[{"author_name":"Oliver Scherf-Clavel","author_inst":"University of Wuerzburg"},{"author_name":"Martina Kinzig","author_inst":"Institute for Biomedical and Pharmaceutical Research"},{"author_name":"Bettina Friedl","author_inst":"University of Wuerzburg"},{"author_name":"Edith Kaczmarek","author_inst":"University of Veterinary Medicine Hannover"},{"author_name":"Malte Feja","author_inst":"University of Veterinary Medicine Hannover"},{"author_name":"Manuela Gernert","author_inst":"University of Veterinary Medicine Hannover"},{"author_name":"Franziska Richter","author_inst":"University of Veterinary Medicine Hannover"},{"author_name":"Rainer Hoehl","author_inst":"Paracelsus Medical Private University"},{"author_name":"Roland Nau","author_inst":"University Medical Center Goettingen"},{"author_name":"Ulrike Holzgrabe","author_inst":"University of Wuerzburg"},{"author_name":"Fritz Soergel","author_inst":"Institute for Biomedical and Pharmaceutical Research, Paul-Ehrlich-Strasse 19, D-90562 Nuernberg-Heroldsberg"},{"author_name":"Javier Gasulla","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Natalia Gorojovsky","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Quimica Biologica. Buenos Aires, Argentina."},{"author_name":"Gustavo E. Gudesblat","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Maria G. Herrera","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Lorena I. Iba\u00f1ez","author_inst":"Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET). Instituto de Ciencia y Tecnologia Dr. Cesar Milstein, Saladillo 2468, C1440FFX Buenos Aire"},{"author_name":"Tommy Idrovo","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Matias Iglesias Rando","author_inst":"Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Quimica Biologica. Junin 965 C1113AAD, Buenos Aires, Argentina."},{"author_name":"Laura Kamenetzky","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Alejandro D Nadra","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Diego G. Noseda","author_inst":"Universidad Nacional de San Martin - CONICET. Instituto de Investigaciones Biotecnologicas (IIBio). San Martin, Buenos Aires, Argentina."},{"author_name":"Carlos H. Pavan","author_inst":"Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica. Buenos Aires, Argentina."},{"author_name":"Maria F. Pavan","author_inst":"Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET). Instituto de Ciencia y Tecnologia Dr. Cesar Milstein, Saladillo 2468, C1440FFX Buenos Aire"},{"author_name":"Maria F. Pignataro","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Ernesto Roman","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Quimica Biologica. Buenos Aires, Argentina."},{"author_name":"Lucas A.M Ruberto","author_inst":"Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Microbiologia, Inmunologia, Biotecnologia y Genetica. Buenos Aires, Argentina."},{"author_name":"Natalia Rubinstein","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Javier Santos","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Francisco Velazquez","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Alicia M. Zelada","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Laboratorio de Agrobiotecnolog"},{"author_name":"Catherine M.K. Ho","author_inst":"Public Health England"},{"author_name":"Chelsea L Kennard","author_inst":"Public Health England"},{"author_name":"Daniel Knott","author_inst":"Public Health England"},{"author_name":"Stephanie Leung","author_inst":"Public Health England"},{"author_name":"Vanessa Lucas","author_inst":"Public Health England"},{"author_name":"Adam Mabbutt","author_inst":"Public Health England"},{"author_name":"Alexandra L Morrison","author_inst":"Public Health England"},{"author_name":"Didier Ngabo","author_inst":"Public Health England"},{"author_name":"Jemma Paterson","author_inst":"Public Health England"},{"author_name":"Elizabeth J Penn","author_inst":"Public Health England"},{"author_name":"Steve Pullan","author_inst":"Public Health England"},{"author_name":"Irene Taylor","author_inst":"Public Health England"},{"author_name":"Tom Tipton","author_inst":"Public Health England"},{"author_name":"Stephen Thomas","author_inst":"Public Health England"},{"author_name":"Julia A Tree","author_inst":"Public Health England"},{"author_name":"Carrie Turner","author_inst":"Public Health England"},{"author_name":"Nadina Wand","author_inst":"Public Health England"},{"author_name":"Nathan R Wiblin","author_inst":"Public Health England"},{"author_name":"Sue Charlton","author_inst":"Public Health England"},{"author_name":"Bassam Hallis","author_inst":"Public Health England"},{"author_name":"Geoffrey Pearson","author_inst":"Public Health England"},{"author_name":"Emma L Rayner","author_inst":"Public Health England"},{"author_name":"Andrew G Nicholson","author_inst":"Public Health England"},{"author_name":"Simon G Funnell","author_inst":"Public Health England"},{"author_name":"Mike J Dennis","author_inst":"Public Health England"},{"author_name":"Fergus V Gleeson","author_inst":"National Heart and Lung Institute"},{"author_name":"Sally Sharpe","author_inst":"Public Health England"},{"author_name":"Miles W Carroll","author_inst":"Public Health England"}],"version":"1","license":"cc_no","type":"new results","category":"systems biology"},{"rel_doi":"10.1101\/2020.09.16.297945","rel_title":"Characterisation of protease activity during SARS-CoV-2 infection identifies novel viral cleavage sites and cellular targets for drug repurposing","rel_date":"2020-09-16","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.16.297945","rel_abs":"SARS-CoV-2 is the causative agent behind the COVID-19 pandemic, and responsible for tens of millions of infections, and hundreds of thousands of deaths worldwide. Efforts to test, treat and vaccinate against this pathogen all benefit from an improved understanding of the basic biology of SARS-CoV-2. Both viral and cellular proteases play a crucial role in SARS-CoV-2 replication, and inhibitors targeting proteases have already shown success at inhibiting SARS-CoV-2 in cell culture models. Here, we study proteolytic cleavage of viral and cellular proteins in two cell line models of SARS-CoV-2 replication using mass spectrometry to identify protein neo-N-termini generated through protease activity. We identify multiple previously unknown cleavage sites in multiple viral proteins, including major antigenic proteins S and N, which are the main targets for vaccine and antibody testing efforts. We discovered significant increases in cellular cleavage events consistent with cleavage by SARS-CoV-2 main protease, and identify 14 potential high-confidence substrates of the main and papain-like proteases. We showed that siRNA depletion of these cellular proteins inhibits SARS-CoV-2 replication, and that drugs targeting two of these proteins: the tyrosine kinase SRC and Ser\/Thr kinase MYLK, showed a dose-dependent reduction in SARS-CoV-2 titres. Overall, our study provides a powerful resource to understand proteolysis in the context of viral infection, and to inform the development of targeted strategies to inhibit SARS-CoV-2 and treat COVID-19 disease.","rel_num_authors":10,"rel_authors":[{"author_name":"Bjoern Meyer","author_inst":"Institut Pasteur"},{"author_name":"Jeanne Chiaravalli","author_inst":"Institut Pasteur"},{"author_name":"Philip Brownridge","author_inst":"University of Liverpool"},{"author_name":"Dominic P. Bryne","author_inst":"University of Liverpool"},{"author_name":"Leonard A. Daly","author_inst":"University of Liverpool"},{"author_name":"Fabrice Agou","author_inst":"Institut Pasteur"},{"author_name":"Claire E. Eyers","author_inst":"University of Liverpool"},{"author_name":"Patrick A. Eyers","author_inst":"University of Liverpool"},{"author_name":"Marco Vignuzzi","author_inst":"Institut Pasteur"},{"author_name":"Edward Emmott","author_inst":"University of Liverpool"},{"author_name":"Fritz Soergel","author_inst":"Institute for Biomedical and Pharmaceutical Research, Paul-Ehrlich-Strasse 19, D-90562 Nuernberg-Heroldsberg"},{"author_name":"Javier Gasulla","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Natalia Gorojovsky","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Quimica Biologica. Buenos Aires, Argentina."},{"author_name":"Gustavo E. Gudesblat","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Maria G. Herrera","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Lorena I. Iba\u00f1ez","author_inst":"Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET). Instituto de Ciencia y Tecnologia Dr. Cesar Milstein, Saladillo 2468, C1440FFX Buenos Aire"},{"author_name":"Tommy Idrovo","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Matias Iglesias Rando","author_inst":"Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Quimica Biologica. Junin 965 C1113AAD, Buenos Aires, Argentina."},{"author_name":"Laura Kamenetzky","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Alejandro D Nadra","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Diego G. Noseda","author_inst":"Universidad Nacional de San Martin - CONICET. Instituto de Investigaciones Biotecnologicas (IIBio). San Martin, Buenos Aires, Argentina."},{"author_name":"Carlos H. Pavan","author_inst":"Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica. Buenos Aires, Argentina."},{"author_name":"Maria F. Pavan","author_inst":"Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET). Instituto de Ciencia y Tecnologia Dr. Cesar Milstein, Saladillo 2468, C1440FFX Buenos Aire"},{"author_name":"Maria F. Pignataro","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Ernesto Roman","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Quimica Biologica. Buenos Aires, Argentina."},{"author_name":"Lucas A.M Ruberto","author_inst":"Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Microbiologia, Inmunologia, Biotecnologia y Genetica. Buenos Aires, Argentina."},{"author_name":"Natalia Rubinstein","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Javier Santos","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Francisco Velazquez","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Alicia M. Zelada","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Laboratorio de Agrobiotecnolog"},{"author_name":"Catherine M.K. Ho","author_inst":"Public Health England"},{"author_name":"Chelsea L Kennard","author_inst":"Public Health England"},{"author_name":"Daniel Knott","author_inst":"Public Health England"},{"author_name":"Stephanie Leung","author_inst":"Public Health England"},{"author_name":"Vanessa Lucas","author_inst":"Public Health England"},{"author_name":"Adam Mabbutt","author_inst":"Public Health England"},{"author_name":"Alexandra L Morrison","author_inst":"Public Health England"},{"author_name":"Didier Ngabo","author_inst":"Public Health England"},{"author_name":"Jemma Paterson","author_inst":"Public Health England"},{"author_name":"Elizabeth J Penn","author_inst":"Public Health England"},{"author_name":"Steve Pullan","author_inst":"Public Health England"},{"author_name":"Irene Taylor","author_inst":"Public Health England"},{"author_name":"Tom Tipton","author_inst":"Public Health England"},{"author_name":"Stephen Thomas","author_inst":"Public Health England"},{"author_name":"Julia A Tree","author_inst":"Public Health England"},{"author_name":"Carrie Turner","author_inst":"Public Health England"},{"author_name":"Nadina Wand","author_inst":"Public Health England"},{"author_name":"Nathan R Wiblin","author_inst":"Public Health England"},{"author_name":"Sue Charlton","author_inst":"Public Health England"},{"author_name":"Bassam Hallis","author_inst":"Public Health England"},{"author_name":"Geoffrey Pearson","author_inst":"Public Health England"},{"author_name":"Emma L Rayner","author_inst":"Public Health England"},{"author_name":"Andrew G Nicholson","author_inst":"Public Health England"},{"author_name":"Simon G Funnell","author_inst":"Public Health England"},{"author_name":"Mike J Dennis","author_inst":"Public Health England"},{"author_name":"Fergus V Gleeson","author_inst":"National Heart and Lung Institute"},{"author_name":"Sally Sharpe","author_inst":"Public Health England"},{"author_name":"Miles W Carroll","author_inst":"Public Health England"}],"version":"1","license":"cc_by","type":"new results","category":"microbiology"},{"rel_doi":"10.1101\/2020.09.16.298992","rel_title":"Efficient production of Moloney murine leukemia virus-like particles pseudotyped with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein","rel_date":"2020-09-16","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.16.298992","rel_abs":"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak that started in China at the end of 2019 has rapidly spread to become pandemic. Several investigational vaccines that have already been tested in animals and humans were able to induce neutralizing antibodies against the SARS-CoV-2 spike (S) protein, however protection and long-term efficacy in humans remain to be demonstrated.\n\nWe have investigated if a virus-like particle (VLP) derived from Moloney murine leukemia virus (MLV) could be engineered to become a candidate SARS-CoV-2 vaccine amenable to mass production. First, we showed that a codon optimized version of the S protein could migrate efficiently to the cell membrane. However, efficient production of infectious viral particles was only achieved with stable expression of a shorter version of S in its C-terminal domain ({Delta}S) in 293 cells that express MLV Gag-Pol (293GP). The incorporation of {Delta}S was 15-times more efficient into VLPs as compared to the full-length version, and that was not due to steric interference between the S cytoplasmic tail and the MLV capsid. Indeed, a similar result was also observed with extracellular vesicles released from parental 293 and 293GP cells. The amount of {Delta}S incorporated into VLPs released from producer cells was robust, with an estimated 1.25 g\/ml S2 equivalent (S is comprised of S1 and S2). Thus, a scalable platform that has the potential for production of pan-coronavirus VLP vaccines has been established. The resulting nanoparticles could potentially be used alone or as a boost for other immunization strategies for COVID-19.\n\nIMPORTANCESeveral candidate COVID-19 vaccines have already been tested in humans, but their protective effect and long-term efficacy are uncertain. Therefore, it is necessary to continue developing new vaccine strategies that could be more potent and\/or that would be easier to manufacture in large-scale. Virus-like particle (VLP) vaccines are considered highly immunogenic and have been successfully developed for human papilloma virus as well as hepatitis and influenza viruses. In this study, we report the generation of a robust Moloney murine leukemia virus platform that produces VLPs containing the spike of SARS-CoV-2. This vaccine platform that is compatible with lyophilization could simplify storage and distribution logistics immensely.","rel_num_authors":4,"rel_authors":[{"author_name":"Manuel Caruso","author_inst":"Laval Universty"},{"author_name":"Sylvie Roy","author_inst":"CRCHUQ-Laval University"},{"author_name":"Karim Ghani","author_inst":"CRCHUQ-Laval University"},{"author_name":"Pedro Otavio de Campos-Lima","author_inst":"State University of Campinas"},{"author_name":"Leonard A. Daly","author_inst":"University of Liverpool"},{"author_name":"Fabrice Agou","author_inst":"Institut Pasteur"},{"author_name":"Claire E. Eyers","author_inst":"University of Liverpool"},{"author_name":"Patrick A. Eyers","author_inst":"University of Liverpool"},{"author_name":"Marco Vignuzzi","author_inst":"Institut Pasteur"},{"author_name":"Edward Emmott","author_inst":"University of Liverpool"},{"author_name":"Fritz Soergel","author_inst":"Institute for Biomedical and Pharmaceutical Research, Paul-Ehrlich-Strasse 19, D-90562 Nuernberg-Heroldsberg"},{"author_name":"Javier Gasulla","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Natalia Gorojovsky","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Quimica Biologica. Buenos Aires, Argentina."},{"author_name":"Gustavo E. Gudesblat","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Maria G. Herrera","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Lorena I. Iba\u00f1ez","author_inst":"Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET). Instituto de Ciencia y Tecnologia Dr. Cesar Milstein, Saladillo 2468, C1440FFX Buenos Aire"},{"author_name":"Tommy Idrovo","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Matias Iglesias Rando","author_inst":"Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Quimica Biologica. Junin 965 C1113AAD, Buenos Aires, Argentina."},{"author_name":"Laura Kamenetzky","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Alejandro D Nadra","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Diego G. Noseda","author_inst":"Universidad Nacional de San Martin - CONICET. Instituto de Investigaciones Biotecnologicas (IIBio). San Martin, Buenos Aires, Argentina."},{"author_name":"Carlos H. Pavan","author_inst":"Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica. Buenos Aires, Argentina."},{"author_name":"Maria F. Pavan","author_inst":"Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET). Instituto de Ciencia y Tecnologia Dr. Cesar Milstein, Saladillo 2468, C1440FFX Buenos Aire"},{"author_name":"Maria F. Pignataro","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Ernesto Roman","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Quimica Biologica. Buenos Aires, Argentina."},{"author_name":"Lucas A.M Ruberto","author_inst":"Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Microbiologia, Inmunologia, Biotecnologia y Genetica. Buenos Aires, Argentina."},{"author_name":"Natalia Rubinstein","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Javier Santos","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Francisco Velazquez","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Alicia M. Zelada","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Laboratorio de Agrobiotecnolog"},{"author_name":"Catherine M.K. Ho","author_inst":"Public Health England"},{"author_name":"Chelsea L Kennard","author_inst":"Public Health England"},{"author_name":"Daniel Knott","author_inst":"Public Health England"},{"author_name":"Stephanie Leung","author_inst":"Public Health England"},{"author_name":"Vanessa Lucas","author_inst":"Public Health England"},{"author_name":"Adam Mabbutt","author_inst":"Public Health England"},{"author_name":"Alexandra L Morrison","author_inst":"Public Health England"},{"author_name":"Didier Ngabo","author_inst":"Public Health England"},{"author_name":"Jemma Paterson","author_inst":"Public Health England"},{"author_name":"Elizabeth J Penn","author_inst":"Public Health England"},{"author_name":"Steve Pullan","author_inst":"Public Health England"},{"author_name":"Irene Taylor","author_inst":"Public Health England"},{"author_name":"Tom Tipton","author_inst":"Public Health England"},{"author_name":"Stephen Thomas","author_inst":"Public Health England"},{"author_name":"Julia A Tree","author_inst":"Public Health England"},{"author_name":"Carrie Turner","author_inst":"Public Health England"},{"author_name":"Nadina Wand","author_inst":"Public Health England"},{"author_name":"Nathan R Wiblin","author_inst":"Public Health England"},{"author_name":"Sue Charlton","author_inst":"Public Health England"},{"author_name":"Bassam Hallis","author_inst":"Public Health England"},{"author_name":"Geoffrey Pearson","author_inst":"Public Health England"},{"author_name":"Emma L Rayner","author_inst":"Public Health England"},{"author_name":"Andrew G Nicholson","author_inst":"Public Health England"},{"author_name":"Simon G Funnell","author_inst":"Public Health England"},{"author_name":"Mike J Dennis","author_inst":"Public Health England"},{"author_name":"Fergus V Gleeson","author_inst":"National Heart and Lung Institute"},{"author_name":"Sally Sharpe","author_inst":"Public Health England"},{"author_name":"Miles W Carroll","author_inst":"Public Health England"}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"microbiology"},{"rel_doi":"10.1101\/2020.09.16.299362","rel_title":"Structure Model Analysis Of Phosphorylation Dependent Binding And Sequestration Of SARS-COV-2 Encoded Nucleocapsid Protein By Protein 14-3-3","rel_date":"2020-09-16","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.16.299362","rel_abs":"Phosphorylation of serines 197 and 206 of SARS-COV-2 Nucleocapsid protein (NCp) enhanced the stability and binding efficiency and sequestration of NCp to Protein 14-3-3 by increasing the Stability Energy ({Delta}Gstability energy) and Binding Energy ({Delta}{Delta}Gbinding energy) from ~545 Kcal\/mol to ~616 Kcal\/mol, and from 108 Kcal\/mol to ~228 Kcal\/mol respectively. The calculated Binding Energy Difference ({Delta}{Delta}Gbinding energy difference) between dephospho-NCp-14-3-3 complex and phospho-NCp-13-3-3 complex was ~72 Kcal\/mol. Phosphorylations of serines 186, 197, 202 and 206, and threonines 198 and 205 NCp also caused an increase in the Stability Energy ({Delta}Gstability energy) and Binding Energy ({Delta}{Delta}Gbinding energy) from ~545 Kcal\/mol to ~617, 616, 583, 580, 574, 564 and 566 Kcal\/mol and from ~108 Kcal\/mol to ~228, 216, 184, 188, 184, 174 and 112 Kcal\/mol respectively. Phosphorylation of NCp on serines 197 and 206 caused a decrease in Stability Energy and Binding Energy from ~698 Kcal\/mol to 688 Kcal\/mol, and from ~91 Kcal\/mol to ~82 Kcal\/mol for the dimerization of NCp. These results support the existence of a phosphorylation dependent cellular mechanism to bind and sequester NCp.","rel_num_authors":2,"rel_authors":[{"author_name":"H.Y. Lim Tung","author_inst":"Nacbraht Biomedical Research Institute"},{"author_name":"Pierre Limtung","author_inst":"Nacbraht Biomedical Research Institute"},{"author_name":"Karim Ghani","author_inst":"CRCHUQ-Laval University"},{"author_name":"Pedro Otavio de Campos-Lima","author_inst":"State University of Campinas"},{"author_name":"Leonard A. Daly","author_inst":"University of Liverpool"},{"author_name":"Fabrice Agou","author_inst":"Institut Pasteur"},{"author_name":"Claire E. Eyers","author_inst":"University of Liverpool"},{"author_name":"Patrick A. Eyers","author_inst":"University of Liverpool"},{"author_name":"Marco Vignuzzi","author_inst":"Institut Pasteur"},{"author_name":"Edward Emmott","author_inst":"University of Liverpool"},{"author_name":"Fritz Soergel","author_inst":"Institute for Biomedical and Pharmaceutical Research, Paul-Ehrlich-Strasse 19, D-90562 Nuernberg-Heroldsberg"},{"author_name":"Javier Gasulla","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Natalia Gorojovsky","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Quimica Biologica. Buenos Aires, Argentina."},{"author_name":"Gustavo E. Gudesblat","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Maria G. Herrera","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Lorena I. Iba\u00f1ez","author_inst":"Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET). Instituto de Ciencia y Tecnologia Dr. Cesar Milstein, Saladillo 2468, C1440FFX Buenos Aire"},{"author_name":"Tommy Idrovo","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Matias Iglesias Rando","author_inst":"Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Quimica Biologica. Junin 965 C1113AAD, Buenos Aires, Argentina."},{"author_name":"Laura Kamenetzky","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Alejandro D Nadra","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Diego G. Noseda","author_inst":"Universidad Nacional de San Martin - CONICET. Instituto de Investigaciones Biotecnologicas (IIBio). San Martin, Buenos Aires, Argentina."},{"author_name":"Carlos H. Pavan","author_inst":"Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica. Buenos Aires, Argentina."},{"author_name":"Maria F. Pavan","author_inst":"Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET). Instituto de Ciencia y Tecnologia Dr. Cesar Milstein, Saladillo 2468, C1440FFX Buenos Aire"},{"author_name":"Maria F. Pignataro","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Ernesto Roman","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Quimica Biologica. Buenos Aires, Argentina."},{"author_name":"Lucas A.M Ruberto","author_inst":"Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Microbiologia, Inmunologia, Biotecnologia y Genetica. Buenos Aires, Argentina."},{"author_name":"Natalia Rubinstein","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Javier Santos","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Francisco Velazquez","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Instituto de Biociencias, Biot"},{"author_name":"Alicia M. Zelada","author_inst":"Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Fisiologia y Biologia Molecular y Celular. Laboratorio de Agrobiotecnolog"},{"author_name":"Catherine M.K. Ho","author_inst":"Public Health England"},{"author_name":"Chelsea L Kennard","author_inst":"Public Health England"},{"author_name":"Daniel Knott","author_inst":"Public Health England"},{"author_name":"Stephanie Leung","author_inst":"Public Health England"},{"author_name":"Vanessa Lucas","author_inst":"Public Health England"},{"author_name":"Adam Mabbutt","author_inst":"Public Health England"},{"author_name":"Alexandra L Morrison","author_inst":"Public Health England"},{"author_name":"Didier Ngabo","author_inst":"Public Health England"},{"author_name":"Jemma Paterson","author_inst":"Public Health England"},{"author_name":"Elizabeth J Penn","author_inst":"Public Health England"},{"author_name":"Steve Pullan","author_inst":"Public Health England"},{"author_name":"Irene Taylor","author_inst":"Public Health England"},{"author_name":"Tom Tipton","author_inst":"Public Health England"},{"author_name":"Stephen Thomas","author_inst":"Public Health England"},{"author_name":"Julia A Tree","author_inst":"Public Health England"},{"author_name":"Carrie Turner","author_inst":"Public Health England"},{"author_name":"Nadina Wand","author_inst":"Public Health England"},{"author_name":"Nathan R Wiblin","author_inst":"Public Health England"},{"author_name":"Sue Charlton","author_inst":"Public Health England"},{"author_name":"Bassam Hallis","author_inst":"Public Health England"},{"author_name":"Geoffrey Pearson","author_inst":"Public Health England"},{"author_name":"Emma L Rayner","author_inst":"Public Health England"},{"author_name":"Andrew G Nicholson","author_inst":"Public Health England"},{"author_name":"Simon G Funnell","author_inst":"Public Health England"},{"author_name":"Mike J Dennis","author_inst":"Public Health England"},{"author_name":"Fergus V Gleeson","author_inst":"National Heart and Lung Institute"},{"author_name":"Sally Sharpe","author_inst":"Public Health England"},{"author_name":"Miles W Carroll","author_inst":"Public Health England"}],"version":"1","license":"cc_no","type":"new results","category":"molecular biology"},{"rel_doi":"10.1101\/2020.09.16.300277","rel_title":"Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques","rel_date":"2020-09-16","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.16.300277","rel_abs":"Effective therapeutics aimed at mitigating COVID-19 symptoms are urgently needed. SARS-CoV-2 induced hypercytokinemia and systemic inflammation are associated with disease severity. Baricitinib, a clinically approved JAK1\/2 inhibitor with potent anti-inflammatory properties is currently being investigated in COVID-19 human clinical trials. Recent reports suggest that baricitinib may also have antiviral activity in limiting viral endocytosis. Here, we investigated the immunologic and virologic efficacy of baricitinib in a rhesus macaque model of SARS-CoV-2 infection. Viral shedding measured from nasal and throat swabs, bronchoalveolar lavages and tissues was not reduced with baricitinib. Type I IFN antiviral responses and SARS-CoV-2 specific T cell responses remained similar between the two groups. Importantly, however, animals treated with baricitinib showed reduced immune activation, decreased infiltration of neutrophils into the lung, reduced NETosis activity, and more limited lung pathology. Moreover, baricitinib treated animals had a rapid and remarkably potent suppression of alveolar macrophage derived production of cytokines and chemokines responsible for inflammation and neutrophil recruitment. These data support a beneficial role for, and elucidate the immunological mechanisms underlying, the use of baricitinib as a frontline treatment for severe inflammation induced by SARS-CoV-2 infection.","rel_num_authors":43,"rel_authors":[{"author_name":"Timothy N Hoang","author_inst":"Emory University"},{"author_name":"Maria Pino","author_inst":"Emory University"},{"author_name":"Arun K Boddapati","author_inst":"Emory University"},{"author_name":"Elise G Viox","author_inst":"Emory University"},{"author_name":"Carly E Starke","author_inst":"Oregon Health & Science University"},{"author_name":"Amit A Upadhyay","author_inst":"Emory University"},{"author_name":"Sanjeev Gumber","author_inst":"Emory University"},{"author_name":"Kathleen Busman-Sahay","author_inst":"Oregon Health & Science University"},{"author_name":"Zachary Strongin","author_inst":"Emory University"},{"author_name":"Justin L Harper","author_inst":"Emory University"},{"author_name":"Gregory K Tharp","author_inst":"Emory University"},{"author_name":"Kathryn L Pellegrini","author_inst":"Emory University"},{"author_name":"Shannon Kirejczyk","author_inst":"Emory University"},{"author_name":"Keivan Zandi","author_inst":"Emory University"},{"author_name":"Sijia Tao","author_inst":"Emory University"},{"author_name":"Tristan R Horton","author_inst":"Emory University"},{"author_name":"Elizabeth N Beagle","author_inst":"Emory University"},{"author_name":"Ernestine A Mahar","author_inst":"Emory University"},{"author_name":"Michelle YH Lee","author_inst":"Emory University"},{"author_name":"Joyce Cohen","author_inst":"Emory University"},{"author_name":"Sherrie Jean","author_inst":"Emory University"},{"author_name":"Jennifer S Wood","author_inst":"Emory University"},{"author_name":"Fawn Connor-Stroud","author_inst":"Emory University"},{"author_name":"Rachelle L Stammen","author_inst":"Emory University"},{"author_name":"Olivia M Delmas","author_inst":"Emory University"},{"author_name":"Shelly Wang","author_inst":"Emory University"},{"author_name":"Kimberly A Cooney","author_inst":"Emory University"},{"author_name":"Michael N Sayegh","author_inst":"Emory University"},{"author_name":"Lanfang Wang","author_inst":"Emory Univeersity"},{"author_name":"Daniela Weiskopf","author_inst":"La Jolla Institute For Allergy & Immunology"},{"author_name":"Peter D Filev","author_inst":"Emory University"},{"author_name":"Jesse Waggoner","author_inst":"Emory University School of Medicine"},{"author_name":"Anne Piantadosi","author_inst":"Emory University School of Medicine"},{"author_name":"Sudhir P Kasturi","author_inst":"Emory University"},{"author_name":"Hilmi Al-Shakhshir","author_inst":"Case Western Reserve University"},{"author_name":"Susan P Ribeiro","author_inst":"Case Western Reserve University"},{"author_name":"Rafick P Sekaly","author_inst":"Case Western Reserve University"},{"author_name":"Rebecca D Levit","author_inst":"Emory University"},{"author_name":"Jacob D Estes","author_inst":"Oregon Health & Science University"},{"author_name":"Thomas H Vanderford","author_inst":"Emory University"},{"author_name":"Raymond F Schinazi","author_inst":"Emory University"},{"author_name":"Steven E Bosinger","author_inst":"Emory University"},{"author_name":"Mirko Paiardini","author_inst":"Emory University"},{"author_name":"Stephen Thomas","author_inst":"Public Health England"},{"author_name":"Julia A Tree","author_inst":"Public Health England"},{"author_name":"Carrie Turner","author_inst":"Public Health England"},{"author_name":"Nadina Wand","author_inst":"Public Health England"},{"author_name":"Nathan R Wiblin","author_inst":"Public Health England"},{"author_name":"Sue Charlton","author_inst":"Public Health England"},{"author_name":"Bassam Hallis","author_inst":"Public Health England"},{"author_name":"Geoffrey Pearson","author_inst":"Public Health England"},{"author_name":"Emma L Rayner","author_inst":"Public Health England"},{"author_name":"Andrew G Nicholson","author_inst":"Public Health England"},{"author_name":"Simon G Funnell","author_inst":"Public Health England"},{"author_name":"Mike J Dennis","author_inst":"Public Health England"},{"author_name":"Fergus V Gleeson","author_inst":"National Heart and Lung Institute"},{"author_name":"Sally Sharpe","author_inst":"Public Health England"},{"author_name":"Miles W Carroll","author_inst":"Public Health England"}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"immunology"},{"rel_doi":"10.1101\/2020.09.16.297366","rel_title":"Bromelain Inhibits SARS-CoV-2 Infection in VeroE6 Cells","rel_date":"2020-09-16","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.09.16.297366","rel_abs":"Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The initial interaction between Transmembrane Serine Protease 2 (TMPRSS2) primed SARS-CoV-2 spike (S) protein and host cell receptor angiotensin-converting enzyme 2 (ACE-2) is a pre-requisite step for this novel coronavirus pathogenesis. Here, we expressed a GFP-tagged SARS-CoV-2 S-Ectodomain in Tni insect cells. That contained sialic acid-enriched N- and O-glycans. Surface resonance plasmon (SPR) and Luminex assay showed that the purified S-Ectodomain binding to human ACE-2 and immunoreactivity with COVID-19 positive samples. We demonstrate that bromelain (isolated from pineapple stem and used as a dietary supplement) treatment diminishes the expression of ACE-2 and TMPRSS2 in VeroE6 cells and dramatically lowers the expression of S-Ectodomain. Importantly, bromelain treatment reduced the interaction between S-Ectodomain and VeroE6 cells. Most importantly, bromelain treatment significantly diminished the SARS-CoV-2 infection in VeroE6 cells. Altogether, our results suggest that bromelain or bromelain rich pineapple stem may be used as an antiviral against COVID-19.\n\nHighlights\n\nO_FIG O_LINKSMALLFIG WIDTH=178 HEIGHT=200 SRC=\"FIGDIR\/small\/297366v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (35K):\norg.highwire.dtl.DTLVardef@b7afb0org.highwire.dtl.DTLVardef@16f8185org.highwire.dtl.DTLVardef@1a07df8org.highwire.dtl.DTLVardef@1ae33fa_HPS_FORMAT_FIGEXP  M_FIG C_FIG O_LIBromelain inhibits \/ cleaves the expression of ACE-2 and TMPRSS2\nC_LIO_LIBromelain cleaves \/ degrades SARS-CoV-2 spike protein\nC_LIO_LIBromelain inhibits S-Ectodomain binding and SARS-CoV-2 infection\nC_LI","rel_num_authors":13,"rel_authors":[{"author_name":"Satish Sagar","author_inst":"University of Nebraska Medical Center"},{"author_name":"Ashok Kumar Rathinavel","author_inst":"University of Nebraska Medical Center"},{"author_name":"William E. Lutz","author_inst":"University of Nebraska Medical Center"},{"author_name":"Lucas R Struble","author_inst":"University of Nebraska Medical Center"},{"author_name":"Surender Khurana","author_inst":"US Food and Drug Administration"},{"author_name":"Andy T Schnaubelt","author_inst":"University of Nebraska Medical Center"},{"author_name":"Nitish K Mishra","author_inst":"University of Nebraska Medical Center"},{"author_name":"Chittibabu Guda","author_inst":"University of Nebraska Medical Center"},{"author_name":"Mara J Broadhurst","author_inst":"University of Nebraska Medical Center"},{"author_name":"St Patrick Reid","author_inst":"University of Nebraska Medical Center"},{"author_name":"Kenneth W Bayles","author_inst":"University of Nebraska Medical Center"},{"author_name":"Gloria E.O Borgstahl","author_inst":"University of Nebraska Medical Center"},{"author_name":"Prakash Radhakrishnan","author_inst":"University of Nebraska Medical Center"},{"author_name":"Keivan Zandi","author_inst":"Emory University"},{"author_name":"Sijia Tao","author_inst":"Emory University"},{"author_name":"Tristan R Horton","author_inst":"Emory University"},{"author_name":"Elizabeth N Beagle","author_inst":"Emory University"},{"author_name":"Ernestine A Mahar","author_inst":"Emory University"},{"author_name":"Michelle YH Lee","author_inst":"Emory University"},{"author_name":"Joyce Cohen","author_inst":"Emory University"},{"author_name":"Sherrie Jean","author_inst":"Emory University"},{"author_name":"Jennifer S Wood","author_inst":"Emory University"},{"author_name":"Fawn Connor-Stroud","author_inst":"Emory University"},{"author_name":"Rachelle L Stammen","author_inst":"Emory University"},{"author_name":"Olivia M Delmas","author_inst":"Emory University"},{"author_name":"Shelly Wang","author_inst":"Emory University"},{"author_name":"Kimberly A Cooney","author_inst":"Emory University"},{"author_name":"Michael N Sayegh","author_inst":"Emory University"},{"author_name":"Lanfang Wang","author_inst":"Emory Univeersity"},{"author_name":"Daniela Weiskopf","author_inst":"La Jolla Institute For Allergy & Immunology"},{"author_name":"Peter D Filev","author_inst":"Emory University"},{"author_name":"Jesse Waggoner","author_inst":"Emory University School of Medicine"},{"author_name":"Anne Piantadosi","author_inst":"Emory University School of Medicine"},{"author_name":"Sudhir P Kasturi","author_inst":"Emory University"},{"author_name":"Hilmi Al-Shakhshir","author_inst":"Case Western Reserve University"},{"author_name":"Susan P Ribeiro","author_inst":"Case Western Reserve University"},{"author_name":"Rafick P Sekaly","author_inst":"Case Western Reserve University"},{"author_name":"Rebecca D Levit","author_inst":"Emory University"},{"author_name":"Jacob D Estes","author_inst":"Oregon Health & Science University"},{"author_name":"Thomas H Vanderford","author_inst":"Emory University"},{"author_name":"Raymond F Schinazi","author_inst":"Emory University"},{"author_name":"Steven E Bosinger","author_inst":"Emory University"},{"author_name":"Mirko Paiardini","author_inst":"Emory University"},{"author_name":"Stephen Thomas","author_inst":"Public Health England"},{"author_name":"Julia A Tree","author_inst":"Public Health England"},{"author_name":"Carrie Turner","author_inst":"Public Health England"},{"author_name":"Nadina Wand","author_inst":"Public Health England"},{"author_name":"Nathan R Wiblin","author_inst":"Public Health England"},{"author_name":"Sue Charlton","author_inst":"Public Health England"},{"author_name":"Bassam Hallis","author_inst":"Public Health England"},{"author_name":"Geoffrey Pearson","author_inst":"Public Health England"},{"author_name":"Emma L Rayner","author_inst":"Public Health England"},{"author_name":"Andrew G Nicholson","author_inst":"Public Health England"},{"author_name":"Simon G Funnell","author_inst":"Public Health England"},{"author_name":"Mike J Dennis","author_inst":"Public Health England"},{"author_name":"Fergus V Gleeson","author_inst":"National Heart and Lung Institute"},{"author_name":"Sally Sharpe","author_inst":"Public Health England"},{"author_name":"Miles W Carroll","author_inst":"Public Health England"}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"microbiology"}]}



